Next Article in Journal
Neuroimaging in Nonsyndromic Craniosynostosis: Key Concepts to Unlock Innovation
Previous Article in Journal
A Novel Algorithm for Forensic Identification Using Geometric Cranial Patterns in Digital Lateral Cephalometric Radiographs in Forensic Dentistry
Previous Article in Special Issue
EEG-Based Detection of Mild Cognitive Impairment Using DWT-Based Features and Optimization Methods
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence

1
Department of Diagnostic and Interventional Neuroradiology, Eberhard Karls University, University Hospital, 72076 Tübingen, Germany
2
Siemens Healthineers AG, 91052 Erlangen, Germany
3
Siemens Medical Solutions USA, Boston, MA 02478, USA
4
Department of Neurology and Stroke, Neurological Clinic, Eberhard Karls University, University Hospital, 72076 Tübingen, Germany
*
Author to whom correspondence should be addressed.
Diagnostics 2024, 14(17), 1841; https://doi.org/10.3390/diagnostics14171841
Submission received: 15 June 2024 / Revised: 18 August 2024 / Accepted: 20 August 2024 / Published: 23 August 2024
(This article belongs to the Special Issue Artificial Intelligence in Brain Diseases)

Abstract

:
In neuroimaging, there is no equivalent alternative to magnetic resonance imaging (MRI). However, image acquisitions are generally time-consuming, which may limit utilization in some cases, e.g., in patients who cannot remain motionless for long or suffer from claustrophobia, or in the event of extensive waiting times. For multiple sclerosis (MS) patients, MRI plays a major role in drug therapy decision-making. The purpose of this study was to evaluate whether an ultrafast, T2-weighted (T2w), deep learning-enhanced (DL), echo-planar-imaging-based (EPI) fluid-attenuated inversion recovery (FLAIR) sequence (FLAIRUF) that has targeted neurological emergencies so far might even be an option to detect MS lesions of the brain compared to conventional FLAIR sequences. Therefore, 17 MS patients were enrolled prospectively in this exploratory study. Standard MRI protocols and ultrafast acquisitions were conducted at 3 tesla (T), including three-dimensional (3D)-FLAIR, turbo/fast spin-echo (TSE)-FLAIR, and FLAIRUF. Inflammatory lesions were grouped by size and location. Lesion conspicuity and image quality were rated on an ordinal five-point Likert scale, and lesion detection rates were calculated. Statistical analyses were performed to compare results. Altogether, 568 different lesions were found. Data indicated no significant differences in lesion detection (sensitivity and positive predictive value [PPV]) between FLAIRUF and axially reconstructed 3D-FLAIR (lesion size ≥3 mm × ≥2 mm) and no differences in sensitivity between FLAIRUF and TSE-FLAIR (lesion size ≥3 mm total). Lesion conspicuity in FLAIRUF was similar in all brain regions except for superior conspicuity in the occipital lobe and inferior conspicuity in the central brain regions. Further findings include location-dependent limitations of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) as well as artifacts such as spatial distortions in FLAIRUF. In conclusion, FLAIRUF could potentially be an expedient alternative to conventional methods for brain imaging in MS patients since the acquisition can be performed in a fraction of time while maintaining good image quality.

1. Introduction

Echo-planar imaging (EPI) represents a very fast acquisition technique in magnetic resonance imaging (MRI). It was first described by Mansfield in 1977 [1] and has since been refined. In [2], Poustchi-Amin et al. reviewed the main principles of EPI: to reduce the number of excitation pulses, thus reducing the number of repetition time (TR) periods by acquiring multiple k-space lines per shot, i.e., during a repetition period. It can be performed using only one shot (single-shot EPI), which means that k-space is filled completely following one excitation, or otherwise using multiple shots (multi-shot EPI), i.e., a particular fraction (obeying a regular sampling pattern along the phase-encoding direction) of k-space is filled with data within each TR period. This can be achieved by generating repetitive echo train signals. Apart from diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), functional MRI (fMRI), and occasionally T2*-weighted (T2*w) imaging [3], EPI has not been integrated into other routine brain MRI sequences such as fluid-attenuated inversion recovery (FLAIR) for the assessment of inflammatory lesions due to drawbacks in terms of image quality and artifacts.
Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS). Neuro-inflammation thereby results in demyelination and axonal damage with reactive gliosis and lesion formation leading to clinical disability progression [4]. MS is the most frequent demyelinating disease worldwide, with the highest prevalence levels in Europe and North America (over 100/100,000 inhabitants) [5]. Relapsing–remitting multiple sclerosis (RRMS) is the most frequent initial course of MS, and women are affected two to three times (or more) as often as men [5]. According to the McDonald criteria and its later revisions, dissemination of CNS lesions in time and space needs to be fulfilled for diagnosis, thus inevitably requiring appropriate MRI examinations [6,7,8,9]. Again, the diagnosis of MS entails further scans for disease activity and treatment monitoring [10]. For this purpose, a FLAIR sequence is an essential tool for cerebral imaging, and the availability of a fast imaging technique would be relevant in that context, given the high prevalence of this disease and the corresponding costs.
In 1999, Filippi et al. analyzed MS lesion detectability in ultrafast EPI-FLAIR images compared to conventional fast spin-echo FLAIR images. They observed similar lesion numbers for lesions that were greater than ten millimeters in long-axis diameter. Detection of smaller lesions proved inferior using EPI-FLAIR sequences [11]. Owing to specificity reasons, there has been support for a size threshold of white matter lesions to allow the diagnosis of MS [12,13]. According to the McDonald criteria, hyperintense areas are referred to as lesions if they are greater than three millimeters in long axis [6,7,8,9]. Grahl et al. recently reviewed those stipulations about a lesion size threshold and confirmed three millimeters to be a reasonable threshold to account for diagnostic criteria in MS for three-dimensional (3D) MRI acquisitions at 3 tesla (T) [14]. However, the effectiveness of EPI-FLAIR sequences has been far from meeting those targets and has therefore not been a suitable option for routine MRI scans.
In recent years, the evolution of artificial intelligence-based applications has witnessed a substantial surge, and significant advancements in machine learning have gained great attention in the field of medical imaging, opening up unprecedented opportunities [15]. Applied to image reconstruction, these deep learning (DL) techniques provide an improved trade-off between speed, resolution, and signal-to-noise ratio (SNR), and often enable significant reductions in scan times when combined with (highly) accelerated conventional techniques such as parallel imaging (PI) [16,17,18,19]. Alternative methods include compressed sensing (CS) [20,21,22,23], simultaneous multi-slice (SMS) imaging (also known as multiband imaging) [24,25,26,27,28], iterative denoising (ID) [29,30] and synthetic MRI [31,32,33,34,35,36,37,38].
Enabled primarily by DL, the acceleration provided by these techniques has redoubled interest in further investigations. Particularly, the integration of several of these methods with EPI-based imaging has led to the development of ultrafast multi-contrast protocols, providing all contrasts required in an emergency setting (T1, T2, T2*, T2-FLAIR, DWI) [39,40,41,42,43,44,45,46]. There is also an approach to incorporate various contrasts in one sequence [47,48,49,50,51,52]. So far, these methods have not targeted clinical applications that rely to some extent on high-resolution data. Also, current research that focuses on EPI-FLAIR in particular is limited and primarily addresses stroke patients and pediatric patients [53,54,55,56]. In-depth evaluations of MS patient brain images that were acquired using DL-enhanced EPI-FLAIR acquisition techniques have not been conducted to date to our knowledge. Although 3D-FLAIR is clearly given preference over 2D-FLAIR for diagnosis and monitoring of MS [57,58], the purpose of this part of our study was to evaluate whether a 2D ultrafast DL-enhanced EPI-FLAIR (FLAIRUF) sequence of the brain could be an adequate alternative to conventional FLAIR scans.

2. Materials and Methods

2.1. Study Design

This prospective, exploratory study was approved by the institutional review board (Project ID 031/2021BO2). We adhered to the 1964 Declaration of Helsinki and its later amendments. Inclusion criteria were adulthood (≥18 years), a routine MRI examination to be carried out on the 3 T MAGNETOM Vida (Siemens Healthineers AG, Forchheim, Germany) scanner, and at least three of the following five MRI contrasts to be conducted: T1-weighted (T1w), T2w, T2*w, DWI, or T2w FLAIR. Moreover, a criterion for allocation to the MS study group was having MS according to the McDonald criteria (2017) [9]. Exclusion criteria were lack of capacity to consent, missing written informed consent, acute stroke in the lysis time window, or general MRI contraindications, such as non-MRI-compliant implants or severe claustrophobia. As can be seen in Figure 1, 17 MS patients underwent 3 T MRI scans of the brain between May 2021 and March 2022. For details on patient characteristics, see Table 1. All eligible patients gave written informed consent to participate in this voluntary study.

2.2. Imaging Protocol and Image Acquisition

All examinations were conducted using a 3 T MRI scanner (see Section 2.1). We used a 20-channel head and neck coil and applied our standard protocol for patients with MS, incorporating the following contrasts: 3D T1 magnetization prepared rapid gradient echo (MPRAGE), contrast-enhanced 3D T1-MPRAGE, contrast-enhanced axial T1 turbo/fast spin echo (TSE), infratentorial axial T2-TSE, axial DWI, 3D double inversion recovery (DIR), and 3D-T2-FLAIR (FLAIR3D). In three patients, an axial standard T2-TSE-FLAIR (FLAIRTSE) sequence was added as well. Additionally, we acquired the ultrafast axial T2w FLAIRUF research sequence in all patients, along with other ultrafast sequences that are not in the scope of this article (i.e., two native axial T1w contrasts, two contrast-enhanced axial T1w contrasts, axial DWI, and an axial sequence providing a T2*w and a T2w contrast). All native sequences were acquired prior to the contrast agent application, and the standard protocol sequences were acquired in advance of the ultrafast sequences. The acquisition parameters for all three T2w FLAIR sequences (i.e., FLAIRUF, FLAIRTSE, and FLAIR3D) are given in Table 2. By using the FLAIRUF sequence, which takes 0:51 min, the acquisition time can be reduced to almost a sixth of the time required for the FLAIR3D sequence (4:57 min) and nearly a third of the time required for the FLAIRTSE sequence (2:22 min).
After acquisition of the data and extraction of relevant clinical data, imaging data were de-identified using RSNA Clinical Trial Processor (CTP) software (RSNA CTP Java Version 1.8, Radiological Society of North America, Oak Brook, IL, USA) for further evaluation within this trial.

2.3. FLAIRUF Sequence

The FLAIRUF sequence examined in this study was a T2w inversion-recovery double-shot spin-echo EPI sequence; i.e., k-space data for each image were acquired in two shots with interleaved phase-encoding patterns. Each shot consisted of a spin-echo inversion recovery excitation module followed by a 64-echo readout train. In all three FLAIR sequences (FLAIRUF, FLAIRTSE, and FLAIR3D), the PI acceleration factor was two.
In order to alleviate the deterioration in image quality caused by the above-mentioned acceleration techniques, the FLAIRUF sequence has several novel features. One of them is a DL-enhanced processing technique that employs a machine learning-based reconstruction to decrease image noise and residual aliasing [43,44,45,59]. Specifically, the method utilizes an unrolled gradient descent network to produce a high-SNR prior image, which is then used to regularize a final conjugate-gradient SENSE reconstruction (see [43] for further details). The network was trained on data acquired with a 20-channel head matrix coil at 3 T [43,44]. However, the clinical patient images included in our study were not part of the training data. The reconstruction method requires coil sensitivity maps based on the eigenvector-based iterative self-consistent parallel imaging reconstruction technique (ESPIRiT) [60]. Those maps are calculated using fast low-angle shot (FLASH)-based autocalibration scans acquired prior to the slice scans. Furthermore, geometric coil compression was utilized to improve reconstruction performance, reducing reconstruction times [61]. Another novel feature implemented is magnetization transfer (MT) preparation to improve tissue contrast, as described in [62]. In addition, the FLAIRUF sequence utilizes the following techniques to improve image quality, amongst others: field map-based geometric distortion correction [63,64], phase correction scans to mitigate residual Nyquist ghosting, flow attenuation gradients to weaken signals from flowing or pulsating fluids, and automated interleaving of inversion and acquisition modules to further optimize the scan efficiency.

2.4. Image Evaluation

Inflammatory lesions and image quality were evaluated by one reader (M.S.), and all ratings were verified by an experienced neuroradiologist (B.B.) in a consensus reading with the first reader for a final decision.

2.4.1. Lesion Assessment

All inflammatory lesions recorded were documented and listed. Identifiers were assigned, using all sequence contrasts available, particularly axial reconstructions including 3D multiplanar reconstructions (MPRs) of FLAIR3D, DIR, and T1-MPRAGE, plus an axial T2-TSE sequence contrast. The utilization of all these contrasts was referred to as the gold standard (GS). Accordingly, the total amount of lesion counts was referred to as true-positives using GS (TPGS). To each TPGS lesion, the following attributes were assigned (see Figure 2): (1) clearly detectable as a lesion using only the axial reconstruction of FLAIR3D (FLAIR3Da), i.e., true-positive in FLAIR3Da (TP3Da), or not clearly detectable as a lesion using only FLAIR3Da, i.e., false-negative in FLAIR3Da (FN3Da); (2) clearly detectable as a lesion using only the FLAIRUF images (TPUF), or not clearly detectable as a lesion using only the FLAIRUF images (FNUF); (3) lesion size, i.e., lengthwise axial diameter (mm, to the nearest tenth); (4) lesion size category, i.e., lengthwise axial diameter (large [≥3 mm] or small [<3 mm]); (5) location, i.e., brain region (frontal, parietal, temporal, occipital, central [insular lobe, corpus callosum, basal nuclei, diencephalon], or infratentorial [brainstem, cerebellum]).
The following attributes were assigned to only a particular subset of the TPGS lesions (see also Figure 2): (1) lesion width (wide [≥2 mm] or narrow [<2 mm]; axial) and lesion location, according to Barkhof et al. and the McDonald criteria [6,7,8,9,13,65] (characteristic [periventricular, juxta-/cortical, infratentorial] or not characteristic) were both assigned to large (≥3 mm) TPGS lesions only; (2) lesion detectability in FLAIRTSE (TPTSE or FNTSE) was assigned to the subset of TPGS recorded with FLAIRTSE (tseTPGS); (3) lesion conspicuity in FLAIRUF compared with FLAIR3Da counterpart, using an ordinal five-point Likert scale (1 = better/larger in the FLAIRUF images; 2 = equal; 3 = better in the FLAIR3Da images, but classified as a lesion using only the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not at all visible in the FLAIRUF images), was only assigned to the TP3Da lesions; (4) presumed causes for not being detected in FLAIRUF were only assigned to the FNUF lesions; (5) presumed causes for not being detected in FLAIR3Da were only assigned to the FN3Da lesions; (6) presumed causes for not being detected in FLAIRTSE were only assigned to the FNTSE lesions.
False-positive (FP) lesions were recorded and listed separately for FLAIRUF (FPUF), FLAIR3Da (FP3Da), and FLAIRTSE (FPTSE). To each FP lesion, the following attributes were assigned (see Figure 3): (1) size category, i.e., lengthwise axial diameter (large [≥3 mm] or small [<3 mm]); (2) presumed causes for being mistaken for a lesion.

2.4.2. Image Quality Assessment

For the purpose of general image quality assessment, three parameters were employed: signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and artifacts. FLAIRUF, FLAIR3Da, and FLAIRTSE slice series were each rated for SNR and CNR on an ordinal five-point Likert scale (1 = very good; 2 = good; 3 = acceptable; 4 = mediocre but diagnostic; 5 = poor and non-diagnostic). Moreover, all artifacts in the FLAIRUF, FLAIR3Da, and FLAIRTSE images were assessed based on quantity and quality. To this end, FLAIRUF, FLAIR3Da, and FLAIRTSE sequences were classified as to their limitations of diagnostic information in the respective artifact region, using an ordinal five-point Likert scale (0 = No artifact; 1 = Artifact exists, but diagnostic information is not limited; 2 = Artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = Artifact exists, and diagnostic information is limited in the artifact region; 4 = Artifact exists, and diagnostic information is severely limited in the artifact region).
To assess location-dependent SNR and CNR within the FLAIRUF images, the following attributes were assigned to each TPGS lesion (see previous Section): (1) SNR in the vicinity of the lesion (standard or substandard; with reference to the average SNR in FLAIRUF); (2) CNR in the vicinity of the lesion (standard or substandard; with reference to the average CNR in FLAIRUF).

2.5. Statistical Analysis

Statistical analyses were performed post hoc using SPSS (IBM SPSS Statistics Version 29.0.0.0, IBM Corp., Armonk, NY, USA) and Excel (Microsoft Excel for Microsoft 365 MSO Version 2305, Microsoft Corp., Redmond, WA, USA).
In order to compare lesion detection in FLAIRUF with lesion detection in FLAIR3Da, contingency tables were created, correlating TP and FN lesion counts. Also, the counts and presumed causes of FN and FP lesions were contrasted. The sensitivity values (TP/[TP + FN]) and positive predictive values (PPVs; TP/[TP + FP]) as to lesion detection were specified including their 95% Clopper–Pearson confidence intervals (CIs), and FN lesion counts were compared using McNemar’s test (Excel). The same analyses were performed to compare the lesion detection in FLAIRUF with the lesion detection in FLAIRTSE. To ascertain factors that affect the lesion conspicuity within the FLAIRUF images, conspicuity ratings were compared, and grouped by lesion size and location, using the Wilcoxon rank-sum test and the Kruskal–Wallis test (SPSS). With the aim to investigate whether conspicuity ratings might possibly have been biased by lesion size variations among the location groups, lengthwise diameters of the TP3Da lesions were reported for each location (mean/95% CI, standard deviation [SD], median) and compared using the Kruskal–Wallis test (SPSS). Moreover, large TP3Da lesions (≥3 mm) for each brain region were divided into wide (≥2 mm) and narrow (<2 mm) lesions and were further differentiated by conspicuity ratings.
For the purpose of contrasting the ordinal SNR, CNR, and artifact ratings in the FLAIRUF and FLAIR3Da image series, results were reported as median plus interquartile range (IQR) as well as mean ± SD; a Wilcoxon signed-rank test was also performed (SPSS). Similarly, results were reported for comparing FLAIRUF with the FLAIRTSE image series. To ascertain positional factors that affect the SNR and CNR within the FLAIRUF images, the dichotomous SNR and CNR ratings were grouped by location; the proportions of the substandard ratings were determined for each group including 95% Clopper–Pearson CIs. Groups were compared using the chi-squared test (Excel).
In [66], Bender et al. stated that multiple testing corrections are not necessarily required for exploratory trials generating (diverse) hypotheses. Accordingly, adjustment for multiple comparisons was waived for this study. A p-value < 0.05 was considered statistically significant.

3. Results

3.1. Image Acquisitions and Lesions

The image data include seventeen FLAIRUF sequences, seventeen corresponding FLAIR3D sequences, and three additional FLAIRTSE sequences, which could all be acquired from seventeen MRI examinations in sixteen different RRMS patients (twelve males, five females). The patients’ mean age was 29 years, with ages ranging from 21 to 60 years (see Table 1). Lesion counts are schematically visualized in Figures 4 and 8 and listed in detail in Figures 5 and 9. In total, we counted 568 true-positive lesions using the gold standard (TPGS), i.e., actual inflammatory brain lesions detected using all contrasts available, as described in Section 2.4.1. Of the 568 existing lesions, 288 (50.7%) were categorized as ‘large lesions’ (≥3 mm total), and 280 (49.3%) were classed as ‘small lesions’ (<3 mm). Of the 288 large lesions, 171 (59.4%) were named as ‘wide lesions’ (width ≥2 mm), and 117 (40.6%) were labeled ‘narrow lesions’ (width < 2 mm). Taking account of all 568 lesions, there were 542 (95.4%) of them that could be detected using only the FLAIR3Da images, hence referred to as TP3Da lesions. Of the 542 TP3Da lesions, 274 (50.6%) were large and 268 (49.4%) were small. The count of wide large TP3Da lesions was 163 (59.5%), and the count of narrow large TP3Da lesions was 111 (40.5%). The mean count of TPGS lesions and standard deviation per patient was 33 ± 21, with counts ranging from 1 to 87. Taking account of all 288 large TPGS lesions, there were 191 (66.3%) lesions grouped as ‘characteristic MS lesions’, which were subdivided into three groups: 109 (57.1%) periventricular lesions, 44 (23.0%) infratentorial lesions, and 38 (19.9%) (juxta-)cortical lesions. All lesion counts, including TPUF lesions and all corresponding FN lesion counts, correlated with each other, are considered in the following Section.

3.2. Lesion Detection

3.2.1. FLAIRUF Compared with FLAIR3Da

Correlations between TPUF, FNUF, TP3Da, FN3Da, and TPGS lesions are schematically demonstrated in Figure 4. Lesion counts are specified in Figure 5, classified by size (large, small, wide, narrow). All counts of total TP and total FN lesions, as well as FP lesions, in both the FLAIRUF images and FLAIR3Da images, were analyzed, compared, and grouped by size.
The sensitivity and PPV in terms of lesion detection using FLAIRUF compared with FLAIR3Da are analyzed in Table 3 and visualized in Figure 6. For wide lesions, no statistically significant differences could be found in either sensitivity (p = 0.50) or PPV (overlap between confidence intervals). Neither was there a significant difference in PPV for narrow lesions (overlap between confidence intervals). Nevertheless, the sensitivity was significantly inferior in the FLAIRUF images for narrow large lesions (p < 0.001). For small lesions, the PPV was reduced in the FLAIRUF images compared with the FLAIR3Da images (no overlap between confidence intervals), and the sensitivity was considerably lower in the FLAIRUF images compared with the FLAIR3Da images (p < 0.001).
Presumed causes of FN lesions in both image variants are quantified in Table 4 (large) and Table 5 (small). Presumed causes for lesions not being detected using FLAIRUF were (1) lesions were not visible owing to a combination of insufficient levels of spatial resolution, CNR, and SNR; (2) lesions were mistaken for cortex or other physiological structures owing to a combination of insufficient levels of spatial resolution, CNR, and SNR; and (3) lesions were concealed by distortion artifacts. Similarly, presumed causes for lesions not being detected using FLAIR3Da were (1) lesions were mistaken for or masked by (mostly infratentorial) pulsation artifacts; (2) lesions were mistaken for cortex or other physiological structures; and (3) lesions were not visible at all, likely due to low resolution-related lesion contrast. Image examples of FNUF lesions and corresponding TP3Da lesions are given in Figure 7 and Figure 13c. Images of a FN3Da lesion including the corresponding TPUF lesion are shown in Figure 15b.
Frequent causes of FP lesions were in each case: partially imaged cortex or infratentorial pulsation artifacts appearing like lesions. While the former could be observed more frequently than the latter in the FLAIRUF images, they occurred at a similar rate in the FLAIR3Da images. Comprehensive results are reported in Table 6. Image examples of FPUF and FP3Da lesions are given in Figures 15 and 16e.

3.2.2. FLAIRUF Compared with FLAIRTSE

To compare FLAIRUF with FLAIRTSE images, all FLAIRTSE data available were utilized and matched with their FLAIRUF counterparts. TPTSE and FNTSE lesion counts added up to the corresponding subset of TPGS lesion counts (tseTPGS). Again, tseTPGS could be divided into corresponding subsets of TPUF and FNUF lesions each (tseTPUF and tseFNUF). Correlations between tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesions are schematically demonstrated in Figure 8. Lesion counts are given in Figure 9, classified by size (large, small, wide, narrow). Image examples of TP lesions in FLAIRUF, FLAIRTSE, and FLAIR3Da are shown side by side in Figure 10. FPTSE lesion counts along with corresponding tseFPUF counts can be found in Table 10.
The proportions of total TP lesions in both the FLAIRTSE and the corresponding FLAIRUF images are further analyzed in Table 7 and visualized in Figure 11, graded as to size. The sensitivity in terms of lesion detection did not differ significantly between the image variants in large (p = 0.68), wide (p > 0.99), or narrow (p > 0.99) lesion groups. For detecting small lesions, the sensitivity was lower using the FLAIRUF images; however, the difference could not be confirmed statistically (p = 0.08).
Presumed causes of FN lesions in both image variants are quantified in Table 8 (large) and Table 9 (small). Causes for lesions not being detected appear to be relatively similar in the FLAIRUF and FLAIRTSE images: (1) lesions were not visible owing to resolution-associated lesion contrast or did not sufficiently stand out from image noise; and (2) lesions were mistaken for cortex or other physiological structures. Table 10 summarizes the presumed causes of FP lesions.

3.2.3. Dependence on Size and Location within FLAIRUF

Unlike in Section 3.2.1 and Section 3.2.2, the results of ordinal lesion conspicuity ratings of the FLAIRUF images, based on the FLAIR3Da images, are presented in this Section. Comprehensive conspicuity ratings are given in Table 11 and visualized in Figure 12, grouped by lesion size and brain regions. As alluded to in Section 3.2.1, there is a statistically significant difference in terms of lesion conspicuity between large and small FLAIRUF lesions (p < 0.001). Testing for conspicuity differences between frontal, parietal, temporal, occipital, central, and infratentorial lesions was significant within the large lesion group (p = 0.002), but not among small lesions (p = 0.15). Further analysis of large lesions revealed that the differences could be attributed to occipital and central lesions. The conspicuity of large lesions among all the other regions did not differ significantly (p = 0.42). Occipital large lesions proved to be more conspicuous (p = 0.002) and central large lesions proved to be less conspicuous (p = 0.01) compared to all the other large lesions (frontal, parietal, temporal, and infratentorial).
Nevertheless, the results are only valid if they are not biased by other parameters, particularly lesion size variations among the brain regions. Therefore, the average lengthwise lesion diameters are compared in Table 12. The results show that there is no significant or relevant deviation of any group, either for large lesions (p = 0.26) or small lesions (p = 0.06). Moreover, Table 13 demonstrates the distribution of large lesions between wide and narrow lesions, clustered by location. Also, each group is differentiated by conspicuity ratings. In comparison to all the other locations, there were two brain regions where there were relatively more wide lesions than narrow lesions: occipital and infratentorial. The conspicuity ratings of wide infratentorial lesions appear to be better than the conspicuity ratings of narrow infratentorial lesions; however, that did not hold true for occipital lesions (good ratings without exception).

3.3. Image Quality

3.3.1. FLAIRUF Compared with FLAIR3Da

SNR and CNR in the FLAIRUF images were rated significantly inferior compared to the FLAIR3Da images (p < 0.001 each). Rating results are given in Table 14. They represent the overall judgments of the slice series. In fact, there were unequal SNR and CNR levels among the slices, and there was also a positional dependence within one image slice. This is further examined in Section 3.3.3. For image examples, see Figure 13.
Table 15 lists all artifacts that could be identified in each sequence variant and shows detailed results. Image series were rated positive for artifacts in cases where the artifact could be detected in at least one image slice. First of all, spatial distortions occurred in each of the FLAIRUF sequences, and did not appear in any of the FLAIR3D sequences, representing the main difference. Regions of distortions were as follows: frontal, frontobasal, temporopolar, and infratentorial. As an example, see the images of spatial distortions (Figure 14) as well as the image of a temporopolar distortion-related FN lesion in Figure 7d. Furthermore, we observed infratentorial pulsatile flow artifacts in all sequences, in both the FLAIRUF images and the FLAIR3Da images. Pulsation artifacts (infratentorial and supratentorial) in the FLAIRUF images typically appeared as hyperintense or hypointense dots, spots, or streaks. Pulsation artifacts in the FLAIR3Da images, however, typically appeared as grainy, hyperintense artifact bands positioned at the level of the pons. Limitation of diagnostic information was assumed if there was a tendency or possibility of artifacts mimicking or masking lesions. The former mainly applied to the FLAIRUF images, and the latter mainly pertained to the FLAIR3Da images. Infratentorial pulsation artifacts and related limitations of diagnostic information are demonstrated in Figure 15. Aside from that, we found other infrequent minor artifacts that almost do not affect diagnostic information and occur only in the FLAIRUF images: supratentorial pulsation artifacts, frontal chemical shift artifacts due to incomplete fat suppression, central residual aliasing, and spike artifacts. Plus, there were some motion artifacts in one FLAIR3Da image series that could not be seen in the corresponding FLAIRUF images. Image examples of those minor artifacts are presented in Figure 16.
Finally, it must be pointed out that all analyses were confined to the brain parenchyma. The subarachnoid space, the dura mater, the cranium, and the scalp, along with other parts of the head such as the nasal cavity and the paranasal sinuses, the internal and external ear, the oral cavity, the throat, the eyes, the orbits, the cranial nerves, muscles, adipose tissue, and other osseous or chondral structures, are insufficiently delineated in the FLAIRUF images, as can be seen in the image examples.

3.3.2. FLAIRUF Compared with FLAIRTSE

SNR and CNR were rated relatively similar in the FLAIRUF and FLAIRTSE images (see Table 16). However, the low number of paired slice series only serves to provide a rough orientation. Results are overall ratings of the slice series, and positional dependences of SNR and CNR (as demonstrated in Section 3.3.3) seem to be similar in the FLAIRUF and FLAIRTSE images.
Artifacts in the FLAIRUF and FLAIRTSE images are contrasted in Table 17. Again, the small amount of data provides only a rough impression. FLAIRUF results are specified in greater detail in Section 3.3.1. Relevant artifacts in the FLAIRTSE images that have the potential to significantly limit diagnostic information are infratentorial pulsatile flow artifacts, either by masking or mimicking lesions. Typically, they appeared as a streaky, irregular (hyperintense and hypointense) band across the middle of the cerebellum, between the right and left sigmoid sinuses (see Figure 17).

3.3.3. Positional Dependence of SNR and CNR in FLAIRUF

In the FLAIRUF images, the vicinity of each TPGS lesion was rated for relative SNR and CNR levels (substandard or standard/superior; with reference to the average FLAIRUF image quality). Table 18 and Table 19 present the results grouped by brain regions. Within a region, lesion-rich areas are given more weight than lesion-poor areas. Compared to all the other brain regions, the SNR appeared significantly reduced in central and infratentorial brain regions (p < 0.001), and the CNR appeared significantly lower in infratentorial brain regions (p < 0.001). What is not evident from the data and is a distinctive characteristic of the infratentorial region is the highly uneven distribution of SNR levels across this area: from highly substandard (in central areas such as the pons) to highly above average (in peripheral areas such as the posterior lobe of the cerebellum). The CNR, however, appeared to be reduced all over the infratentorial areas; particularly, the fine folium-sulcus texture of the cerebellum could not be distinguished sufficiently. Image examples are given in Figure 18.

4. Discussion

4.1. Main Findings of This Study

This study investigated an ultrafast axial DL-enhanced EPI-FLAIR (FLAIRUF) MRI sequence in RRMS patients. The FLAIRUF sequence reduced the acquisition time to almost a sixth of the time required for conventional three-dimensional FLAIR (FLAIR3D) acquisitions and nearly a third of the time required for axial standard TSE-FLAIR (FLAIRTSE) acquisitions. Based on specific parameters, we investigated lesion detection and image quality in the three sequences. With regard to the detection of inflammatory brain lesions, we did not observe any significant differences between the FLAIRUF images and the FLAIR3Da images in either sensitivity for wide large lesions (≥3 mm × ≥2 mm) or PPV for all large lesions (≥3 mm total) despite the high lesion numbers. The same applies to the sensitivity of large lesion detection (≥3 mm total) in the FLAIRUF images compared to the FLAIRTSE images. Lesion conspicuity did not differ significantly between brain regions in the FLAIRUF images, except for occipital large lesions (superior results) and central large lesions (inferior results). SNR and CNR were significantly inferior using FLAIRUF compared to FLAIR3D, which particularly applied to specific areas of the image. In contrast, SNR and CNR in FLAIRUF appeared to be closely comparable to FLAIRTSE. Unlike FLAIRTSE and FLAIR3D, the image quality in FLAIRUF was limited by distortion artifacts in typical locations. To our knowledge, this study represents the first in-depth quantitative and qualitative evaluation of inflammatory lesions using a DL-enhanced EPI-FLAIR sequence.

4.2. Significance of MRI and Ultrafast MRI

In MS patients, the severity of the clinical course is influenced by the start and choice of disease-modifying therapy (DMT). Notably, early treatment start or treatment escalation delays disease progress of both clinically definite multiple sclerosis (CDMS) and clinically isolated syndrome (CIS) in particular [67]. To decide on adequate therapeutic strategies depending on disease activity, MRI plays a major role [10,67,68]. McDonald diagnostic criteria are based on number, location, and size of lesions as well as temporal changes in lesions [6,7,8,9]. A lesion size of over 3 mm is deemed to be appropriate to account for the diagnostic criteria [14]. In order to adapt DMT without delay, specific monitoring intervals are recommended [10]. Notably, CIS patients benefit from very tight follow-up MRI examinations, particularly during the first year [10,69]. Nonetheless, overall MRI scan capacity is far from enough to satisfy demand in numerous parts of the world, and waiting times usually exceed the maximum recommended time, thus worsening medical outcomes and increasing the economic costs [70,71,72,73,74,75]. Against this background, utilizing DL-enhanced EPI-FLAIR sequences may be a promising approach to ameliorate treatment quality while at the same time meeting diagnostic requirements. It might help facilitate low-threshold access to MRI examinations at an earlier stage and at shorter intervals before MS has been diagnosed. Whether FLAIRUF or related techniques could actually be suitable for monitoring the early stages of the disease still requires further investigation.

4.3. Limitations of the FLAIRUF Images

Despite its remarkable capabilities, the FLAIRUF images still have three primary limitations. First, lesion size is a limiting factor for the FLAIRUF images, particularly in comparison with the FLAIR3Da images. Almost every second small lesion (<3 mm) and more than every fifth narrow large lesion (≥3 mm × <2 mm) could not be detected using the FLAIRUF images. Additionally, out of all presumed small lesions (<3 mm), about a quarter detected using the ultrafast sequence variant were false-positives. There may be one main cause of these limitations: the relatively large slice thickness including slice gaps in this context. It should be noted that this parameter even influenced the detection of large lesions (≥3 mm).
Secondly, lesion location may represent another limiting factor in the FLAIRUF images. There are several location-dependent factors: (1) SNR deterioration toward the central regions of the images, and simultaneously, SNR enhancement toward marginal regions such as the occipital lobe (even though it appears similar compared with the FLAIRTSE images); (2) some limits of CNR, which primarily become apparent when depicting regions that require high spatial resolution and low slice thickness, particularly the cerebellum with its fine folium-sulcus texture (even though the overall CNR only seems marginally reduced compared with the FLAIRTSE images); (3) pulsatile flow artifacts, which mostly affect image quality by mimicking infratentorial lesions (even though infratentorial pulsation artifacts appear to limit image quality to a similar extent using FLAIR3Da or FLAIRTSE, mostly by masking potential lesions); (4) spatial distortion artifacts (frontal, frontobasal, temporopolar, and infratentorial), which may conceal potential lesions; and (5) relatively large slice thickness including slice gaps, which may hinder the distinction between lesions and physiological brain structures at certain locations, particularly near the cortex.
Thirdly, there is an additional limitation apart from those associated with lesion assessment: most structures outside the parenchyma are insufficiently delineated in the FLAIRUF images, such as osseus structures, air-containing structures, or adipose tissue. Reasons for this may be susceptibility artifacts and fat suppression. However, the optic nerves, for example, are clearly distinguishable, and fat suppression might even be advantageous in terms of assessing optic neuritis. However, this remains speculative and beyond the scope of our study.

4.4. Considerations on Ratings for Lesion Conspicuity in FLAIRUF

Ratings for lesion conspicuity in FLAIRUF (Section 3.2.3) were intended to compare results among the brain regions within the FLAIRUF images. Since a kind of reference was required (FLAIR3Da), the ratings appear to be biased by position-dependent lesion conspicuity in FLAIR3Da. However, those potential position-dependent differences did not exist at all in the FLAIR3Da images, and image quality was excellent across all regions. The only exception was infratentorial, where a few lesions were masked by pulsation artifacts (FN lesions); all the other infratentorial lesions were not affected in any way. In order to prevent FLAIR3Da-biased (infratentorial) conspicuity ratings in FLAIRUF, assessments were confined to TP3Da lesions instead of TPGS lesions.
As stated previously, the conspicuity ratings do not seem to be biased by lesion size variations among the brain regions, with one exception: ratings of infratentorial large lesions might have been biased toward falsely positive results, since the proportion of wide lesions to narrow lesions was greater compared to all the other regions, while at the same time, the conspicuity ratings appeared to be superior for wide lesions. That might be an explanation for why the conspicuity ratings do not reflect the substandard SNR and CNR ratings for this region; this discrepancy did not exist in other locations.
Finally, localization-dependent conspicuity results in FLAIRUF could only be demonstrated for large lesions, not for small lesions. The underlying cause could be that slice thickness and slice gaps are the limiting factors for small lesion conspicuity, which is independent of the position. SNR-related positional dependence appears to have a subordinate role in this context. For instance, large central lesions stood out with a comparatively high proportion of grade 3 ratings (conspicuity better in the FLAIR3Da images but classified as a lesion using only the FLAIRUF images), but for small central lesions, that proportion was relatively low in favor of grade 4 and 5 ratings (not classified as a lesion using FLAIRUF). In all the other brain regions, on the contrary, large lesions predominantly exhibited grade 1 and 2 ratings (conspicuity at least equal in the FLAIRUF images), i.e., comparatively small proportions of grade 3 ratings, while for small lesions, that proportion was considerably lower in favor of grade 4 and 5 ratings, comparable to the central small lesion group. However, for occipital and infratentorial small lesions, the counts were insufficient to draw further conclusions regarding the position-dependent conspicuity of small lesions.

4.5. Outcomes Correlated with Technical Features

The above-mentioned characteristics of the FLAIRUF images arise from specific sequence properties. To begin with, there is a correlation between slice thickness (slice gap included) and visibility of small lesions: if the lesion size is smaller than the slice thickness, the signal intensity will decrease, and with it the lesion contrast due to the partial volume effect. At some point, the lesion signal will disappear completely if the lesions are too small. Thus, there is a direct correlation between the threshold and slice thickness.
Apart from the partial volume effect, EPI-related CNR loss seems to be sufficiently counterbalanced by MT preparation [62]. Here, MT pulses serve as saturation pulses selectively affecting macromolecular protons and adjacent water molecules to enhance image contrast [76].
In EPI, the SNR is diminished due to substantial signal loss during its long echo train, and lack of refocusing pulses combined with rapid T2* signal decay. Nevertheless, aided by the DL reconstruction, the SNR in FLAIRUF appeared similar compared to FLAIRTSE. In both image variants, the SNR (and related lesion conspicuity) decreased similarly toward the center of the image, owing to coil dependency in PI [77,78,79]. Accordingly, there is an inversely proportional relationship between SNR and the geometry (g)-factor [77,78,79]. This factor is affected by coil sensitivity and voxel location, usually exhibiting the greatest values in the center of the image [77,78,79]. Although the DL reconstruction method was designed to compensate for this specific factor, its SNR gains were eventually limited, especially in combination with stringent requirements for slice thickness. In contrast, the excellent SNR in FLAIR3D can be attributed to the fact that in 3D acquisitions, the complete volume is excited with each shot.
In addition, the long readout duration in EPI has another significant impact on image quality (together with the very low pixel bandwidth along the phase-encoding direction in EPI): increased sensitivity to susceptibility artifacts [80]. If a substance is located in an external homogeneous magnetic field, the magnetic field lines will either be dispersed (e.g., bone tissue) or concentrated (e.g., air or metal) around that material, depending on its susceptibility properties [81]. Consequently, the magnetic field is disturbed in areas where susceptibility differences are large (e.g., air-filled bones), leading to an accelerated phase coherence loss and T2* signal decay, on the one hand, and accumulation of phase errors along with positioning errors in the phase encoding direction, on the other [2]. This explains the appearance of both distortion artifacts, particularly arising in the vicinity of air–tissue interfaces in the phase encoding direction, and signal decrease in tissues surrounding the brain parenchyma, caused by differences in magnetic susceptibility. In strong magnetic fields, susceptibility differences further increase, and phase incoherences accumulate to a greater extent over the duration of the echo train [2,82,83]. In contrast, SNR, CNR, spatial resolution, and scan time benefit from a strong magnetic field strength [82,83].
Apart from susceptibility effects, there is another reason for the signal decrease in non-parenchymal tissues in FLAIRUF: fat suppression. It is essential for low-segmented EPI in order to avert chemical shift artifacts [2]. Those artifacts derive from spatial signal misregistration owing to frequency differences between protons in fat and water. Without fat suppression, however, the implicitly low pixel bandwidth along the phase-encoding direction in EPI would lead to the accumulation of phase shifts between fat and water, resulting in chemical shift artifacts in the phase-encoding direction [80,84]. With singular exceptions located close to the frontal air–tissue interfaces, we did not observe any chemical shift artifacts caused by incomplete fat suppression in the FLAIRUF images.
In addition, we observed other artifacts caused by phase errors: pulsatile flow artifacts. They usually occur along the phase encoding direction [85]. Accordingly, we were able to relate most artifacts to structures containing flowing blood or liquor in all three image variants (FLAIRUF, FLAIRTSE, and FLAIR3Da), each of them revealing distinctive characteristics. Typically, the artifacts either occurred around blood vessels, particularly around infratentorial venous sinuses (FLAIRUF), or they were aligned in positions shifted from blood vessels along the phase encoding direction (FLAIRUF, FLAIR3Da, and FLAIRTSE). In the FLAIRUF and FLAIR3Da images, artifacts were shifted along the anterior–posterior axis, while in the FLAIRTSE images, artifacts were shifted along the left–right axis (compare Table 2). In the FLAIRUF images, replicas were shifted at intervals of a quarter of the field of view (according to the PI acceleration factor of two and the two-segmented k-space). In the FLAIR3Da and FLAIRTSE images, artifacts manifested as grainy or streaky bands. However, in terms of limitations of diagnostic information caused by pulsation artifacts, the FLAIRUF images were not inferior.
Finally, there were three more rare minor artifacts, two of which could be seen in the FLAIRUF images: residual aliasing and spike artifacts. The former is related to PI reconstruction, and the latter is related to the rapid switching of gradients in EPI. The third artifact type, minor motion artifacts caused by subject movement, could not be observed in the FLAIRUF images, but rather in one FLAIR3Da and one FLAIRTSE image series. This is related to the longer acquisition time in FLAIR3D and FLAIRTSE. In this regard, EPI is undeniably at an advantage.

4.6. Limitations of the Study

There are some limitations of this study that might have affected our results. To begin with, the methodological approach may be associated with some selection bias. Examinations were carried out using one specific scanner, and the patient sample may be biased by common appointment scheduling practices in terms of disease manifestation or severity (medium or low disease activity in an outpatient follow-up setting). Although no patient declined to participate in the study, there were a couple of patients who could not be included from the outset due to the associated additional expenditure of time. That probably led to further sampling bias (e.g., age, sex, clinical condition). In particular, the sex ratio in our study was atypical (compare Section 1 and Section 2.1). Aside from selection bias, there were more factors limiting the external validity, such as the single-center study design using only one single 3 T MRI scanner from one specific manufacturer. In consideration of our methodological objective to analyze lesion detection and image quality in general, it must be pointed out that the comparisons performed could only be based on limited parameters.
Moreover, there might have been some observer bias inherent to this study, despite all efforts and critical appraisal. In this regard, implementing image blinding would not have had a positive effect due to the significantly different and easily distinguishable nature of the images, and the study was designed for subjective side-by-side comparisons. Generally, radiological readers’ assessments may also depend on their level of experience with the FLAIRUF image characteristics.
Even though the number of participants was modest, the lesion counts were substantial, providing high statistical power. Nevertheless, there is an important limitation from a statistical point of view: statistically, several lesions within one subject are not independent observations, because they are bound to both the same individual and time of scan. Accordingly, lesion conspicuity could possibly have been influenced by parameters that might have varied among the individuals or scans, which may have induced statistical bias. Also, non-significant test results are indications, but not proof, of equality. So, in large part, the results of the study are indicative, not conclusive. However, variances among the image data appeared to play a minor role, at most, and non-significant results are more meaningful when based on a large sample size. Methodologically, it would have been precise either to rate all lesions from one image series as a whole or to randomly select and analyze only one lesion from each image series after recording all existing lesions. However, the former procedure would have provided highly inaccurate outcomes, and the latter procedure would have provided relatively meaningless test results (if statistically non-significant), owing to the sample size. In this study, the small FLAIRTSE sample size only provides indicative findings: results were either statistically tested, accepting the possibility of an increased type II error, or statistical testing was omitted.
While the acquisition sequence used in this study would allow for reducing the slice thickness to 3 mm without compromising scan coverage and total scan time, it remains unclear to what extent DL processing may compensate for the corresponding 25% reduction in SNR. Assessing further optimizations of the acquisition protocol may represent a rewarding task for future studies. Also, further prospective studies and confirmatory trials with larger numbers of participants and more diverse cohorts, various scanners, and modified reconstruction and acquisition methods need to be conducted. Further radiological reading should possibly include separate image assessments instead of side-by-side comparisons. Plus, other studies covering MS patients might consider additional contrasts (e.g., contrast-enhanced T1w sequences), orientations (sagittal, coronal), or regions (such as the spinal cord or the optic nerves).

4.7. Future Perspectives

All in all, our results suggest that FLAIRUF may be an appropriate approach for assessing cerebral inflammatory lesions. Diagnostic performance did not prove inferior compared to conventional FLAIR3D in terms of MS lesion detection (≥3 mm × ≥2 mm) in just about a sixth of the time. This demonstrates the tremendous progress made in the field of EPI. In light of extensive waiting times for MRI examinations and patient-dependent constraints to carry them out, for example, claustrophobia or inability to remain motionless (i.e., children or disease- and age-related obstacles), ultrafast imaging seems an essential tool. However, there are still some challenges to overcome in refining this technique while aiming to combine high resolution with high SNR at high field strengths along with low artifacts.

5. Conclusions

In conclusion, this study indicates that ultrafast DL-enhanced EPI-FLAIR might be an appropriate method for the assessment of cerebral inflammatory lesions (≥3 mm) in MS. Apart from relatively minor limitations regarding lesion size and lesion location, it did not prove inferior to conventional FLAIR methods in the main, while being conducted in a fraction of time. In consideration of both MRI waiting times and patients who cannot remain motionless in the scanner for long, EPI might be an expedient alternative to conventional imaging. However, further studies are required to confirm our findings.

Author Contributions

Conceptualization, M.S. and B.B.; methodology, M.S. and B.B.; software, T.F. and B.C.; validation, M.S. and B.B.; formal analysis, M.S. and B.B.; investigation, M.S., C.R., E.B., M.K. and B.B.; resources, M.K.; data curation, M.S.; writing—original draft preparation, M.S.; writing—review and editing, M.S., C.R., E.B., T.F., B.C., M.K. and B.B.; visualization, M.S.; supervision, B.B.; project administration, B.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding. The APC was funded by the Open Access Publication Fund of the University of Tübingen.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the Medical Faculty of the Eberhard Karls University and the University Hospital of Tübingen, Germany (reference number 031/2021BO2, approved on 27 April 2021).

Informed Consent Statement

Informed consent for participation in the study, for publication of the results, and sharing of anonymized data was obtained from all subjects prior to the acquisition of any data.

Data Availability Statement

Anonymized, defaced MRI data can be obtained by the corresponding author upon reasonable request.

Acknowledgments

The authors would like to thank Silke Buschbach for technical support in acquiring the images and data management.

Conflicts of Interest

M.S., C.R., and E.B. declare no conflict of interest. The software prototype used in the study was provided by Siemens Healthineers AG. T.F. is an employee of Siemens Healthineers, owns stock in Siemens (Healthineers) AG, and holds patents filed by Siemens (Healthineers). B.C. is an employee of Siemens Medical Solutions, USA, and holds patents filed by Siemens (Healthineers). M.K. has served on advisory boards and received speaker fees/travel grants from Merck, Sanofi-Genzyme, Novartis, Biogen, Janssen, Alexion, Celgene/Bristol-Myers Squibb, and Roche. He has received research grants from Merck, Roche, Novartis, Sanofi-Genzyme, and Celgene/Bristol-Myers Squibb. B.B. is co-founder, shareholder, and CTO of AIRAmed GmbH. The Open Access Publication Fund had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Mansfield, P. Multi-planar image formation using NMR spin echoes. J. Phys. C Solid State Phys. 1977, 10, L55–L58. [Google Scholar] [CrossRef]
  2. Poustchi-Amin, M.; Mirowitz, S.A.; Brown, J.J.; McKinstry, R.C.; Li, T. Principles and applications of echo-planar imaging: A review for the general radiologist. Radiographics 2001, 21, 767–779. [Google Scholar] [CrossRef] [PubMed]
  3. Kinoshita, T.; Okudera, T.; Tamura, H.; Ogawa, T.; Hatazawa, J. Assessment of Lacunar Hemorrhage Associated With Hypertensive Stroke by Echo-Planar Gradient-Echo T2*-Weighted MRI. Stroke 2000, 31, 1646–1650. [Google Scholar] [CrossRef] [PubMed]
  4. Compston, A.; Coles, A. Multiple sclerosis. Lancet 2008, 372, 1502–1517. [Google Scholar] [CrossRef]
  5. Leray, E.; Moreau, T.; Fromont, A.; Edan, G. Epidemiology of multiple sclerosis. Rev. Neurol. 2016, 172, 3–13. [Google Scholar] [CrossRef]
  6. McDonald, W.I.; Compston, A.; Edan, G.; Goodkin, D.; Hartung, H.P.; Lublin, F.D.; McFarland, H.F.; Paty, D.W.; Polman, C.H.; Reingold, S.C.; et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50, 121–127. [Google Scholar] [CrossRef]
  7. Polman, C.H.; Reingold, S.C.; Edan, G.; Filippi, M.; Hartung, H.-P.; Kappos, L.; Lublin, F.D.; Metz, L.M.; McFarland, H.F.; O′Connor, P.W.; et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann. Neurol. 2005, 58, 840–846. [Google Scholar] [CrossRef]
  8. Polman, C.H.; Reingold, S.C.; Banwell, B.; Clanet, M.; Cohen, J.A.; Filippi, M.; Fujihara, K.; Havrdova, E.; Hutchinson, M.; Kappos, L.; et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 2011, 69, 292–302. [Google Scholar] [CrossRef]
  9. Thompson, A.J.; Banwell, B.L.; Barkhof, F.; Carroll, W.M.; Coetzee, T.; Comi, G.; Correale, J.; Fazekas, F.; Filippi, M.; Freedman, M.S.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef] [PubMed]
  10. Kaunzner, U.W.; Gauthier, S.A. MRI in the assessment and monitoring of multiple sclerosis: An update on best practice. Ther. Adv. Neurol. Disord. 2017, 10, 247–261. [Google Scholar] [CrossRef]
  11. Filippi, M.; Rocca, M.A.; Wiessmann, M.; Mennea, S.; Cercignani, M.; Yousry, T.A.; Sormani, M.P.; Comi, G. A Comparison of MR Imaging with Fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR Sequences in the Assessment of Patients with Multiple Sclerosis. AJNR Am. J. Neuroradiol. 1999, 20, 1931–1938. [Google Scholar] [PubMed]
  12. Gebarski, S.S.; Gabrielsen, T.O.; Gilman, S.; Knake, J.E.; Latack, J.T.; Aisen, A.M. The initial diagnosis of multiple sclerosis: Clinical impact of magnetic resonance imaging. Ann. Neurol. 1985, 17, 469–474. [Google Scholar] [CrossRef] [PubMed]
  13. Barkhof, F.; Filippi, M.; Miller, D.H.; Scheltens, P.; Campi, A.; Polman, C.H.; Comi, G.; Adèr, H.J.; Losseff, N.; Valk, J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120, 2059–2069. [Google Scholar] [CrossRef] [PubMed]
  14. Grahl, S.; Pongratz, V.; Schmidt, P.; Engl, C.; Bussas, M.; Radetz, A.; Gonzalez-Escamilla, G.; Groppa, S.; Zipp, F.; Lukas, C.; et al. Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2019, 29, 124–129. [Google Scholar] [CrossRef]
  15. Selvikvåg Lundervold, A.; Lundervold, A. An overview of deep learning in medical imaging focusing on MRI. Z. Med. Phys. 2019, 29, 102–127. [Google Scholar] [CrossRef] [PubMed]
  16. Radmanesh, A.; Muckley, M.J.; Murrell, T.; Lindsey, E.; Sriram, A.; Knoll, F.; Sodickson, D.K.; Lui, Y.W. Exploring the Acceleration Limits of Deep Learning Variational Network–based Two-dimensional Brain MRI. Radiol. Artif. Intell. 2022, 4, e210313. [Google Scholar] [CrossRef]
  17. Mani, A.; Santini, T.; Puppala, R.; Dahl, M.; Venkatesh, S.; Walker, E.; DeHaven, M.; Isitan, C.; Ibrahim, T.S.; Wang, L.; et al. Applying Deep Learning to Accelerated Clinical Brain Magnetic Resonance Imaging for Multiple Sclerosis. Front. Neurol. 2021, 12, 685276. [Google Scholar] [CrossRef]
  18. Estler, A.; Hauser, T.-K.; Mengel, A.; Brunnée, M.; Zerweck, L.; Richter, V.; Zuena, M.; Schuhholz, M.; Ernemann, U.; Gohla, G. Deep Learning Accelerated Image Reconstruction of Fluid-Attenuated Inversion Recovery Sequence in Brain Imaging: Reduction of Acquisition Time and Improvement of Image Quality. Acad. Radiol. 2024, 31, 180–186. [Google Scholar] [CrossRef]
  19. Iwamura, M.; Ide, S.; Sato, K.; Kakuta, A.; Tatsuo, S.; Nozaki, A.; Wakayama, T.; Ueno, T.; Haga, R.; Kakizaki, M.; et al. Thin-slice Two-dimensional T2-weighted Imaging with Deep Learning-based Reconstruction: Improved Lesion Detection in the Brain of Patients with Multiple Sclerosis. Magn. Reson. Med. Sci. 2024, 23, 184–192. [Google Scholar] [CrossRef]
  20. Toledano-Massiah, S.; Sayadi, A.; de Boer, R.; Gelderblom, J.; Mahdjoub, R.; Gerber, S.; Zuber, M.; Zins, M.; Hodel, J. Accuracy of the Compressed Sensing Accelerated 3D-FLAIR Sequence for the Detection of MS Plaques at 3T. AJNR Am. J. Neuroradiol. 2018, 39, 454–458. [Google Scholar] [CrossRef]
  21. Liebig, P.A.; Heidemann, R.M.; Hensel, B.; Porter, D.A. A new approach to accelerate readout segmented EPI with compressed sensing. Magn. Reson. Med. 2020, 84, 321–326. [Google Scholar] [CrossRef] [PubMed]
  22. Liu, K.; Xi, B.; Sun, H.; Wang, J.; Chen, C.; Wen, X.; Zhang, Y.; Zeng, M. The clinical feasibility of artificial intelligence-assisted compressed sensing single-shot fluid-attenuated inversion recovery (ACS-SS-FLAIR) for evaluation of uncooperative patients with brain diseases: Comparison with the conventional T2-FLAIR with parallel imaging. Acta Radiol. 2022, 64, 1943–1949. [Google Scholar] [CrossRef]
  23. Cristobal-Huerta, A.; Poot, D.H.J.; Vogel, M.W.; Krestin, G.P.; Hernandez-Tamames, J.A. Compressed Sensing 3D-GRASE for faster High-Resolution MRI. Magn. Reson. Med. 2019, 82, 984–999. [Google Scholar] [CrossRef]
  24. Runge, V.M.; Richter, J.K.; Heverhagen, J.T. Simultaneous Multi-Slice—A Concise Review Covering Major Applications in Clinical Practice. MAGNETOM Flash 2017, 68, 96–101. [Google Scholar]
  25. Setsompop, K.; Cauley, S.F.; Wald, L.L. Advancing Diffusion MRI Using Simultaneous Multi-Slice Echo Planar Imaging. MAGNETOM Flash 2015, 63, 16–22. [Google Scholar]
  26. Runge, V.M.; Richter, J.K.; Heverhagen, J.T. Speed in Clinical Magnetic Resonance. Investig. Radiol. 2017, 52, 1–17. [Google Scholar] [CrossRef]
  27. Schulz, J.; Marques, J.P.; ter Telgte, A.; Dorst, A.; de Leeuw, F.-E.; Meijer, F.J.; Norris, D.G. Clinical application of Half Fourier Acquisition Single Shot Turbo Spin Echo (HASTE) imaging accelerated by simultaneous multi-slice acquisition. Eur. J. Radiol. 2018, 98, 200–206. [Google Scholar] [CrossRef]
  28. Cho, J.; Liao, C.; Tian, Q.; Zhang, Z.; Xu, J.; Lo, W.-C.; Poser, B.A.; Stenger, V.A.; Stockmann, J.; Setsompop, K.; et al. Highly accelerated EPI with wave encoding and multi-shot simultaneous multislice imaging. Magn. Reson. Med. 2022, 88, 1180–1197. [Google Scholar] [CrossRef]
  29. Eliezer, M.; Vaussy, A.; Toupin, S.; Barbe, R.; Kannengiesser, S.; Stemmer, A.; Houdart, E. Iterative denoising accelerated 3D SPACE FLAIR sequence for brain MR imaging at 3T. Diagn. Interv. Imaging 2022, 103, 13–20. [Google Scholar] [CrossRef]
  30. Quint, R.; Vaussy, A.; Stemmer, A.; Hautefort, C.; Houdart, E.; Eliezer, M. Iterative Denoising Accelerated 3D FLAIR Sequence for Hydrops MR Imaging at 3T. AJNR Am. J. Neuroradiol. 2023, 44, 1064–1069. [Google Scholar] [CrossRef]
  31. Granberg, T.; Uppman, M.; Hashim, F.; Cananau, C.; Nordin, L.E.; Shams, S.; Berglund, J.; Forslin, Y.; Aspelin, P.; Fredrikson, S.; et al. Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study. AJNR Am. J. Neuroradiol. 2016, 37, 1023–1029. [Google Scholar] [CrossRef] [PubMed]
  32. Hagiwara, A.; Hori, M.; Yokoyama, K.; Takemura, M.; Andica, C.; Tabata, T.; Kamagata, K.; Suzuki, M.; Kumamaru, K.; Nakazawa, M.; et al. Synthetic MRI in the Detection of Multiple Sclerosis Plaques. AJNR Am. J. Neuroradiol. 2017, 38, 257–263. [Google Scholar] [CrossRef]
  33. Hagiwara, A.; Otsuka, Y.; Hori, M.; Tachibana, Y.; Yokoyama, K.; Fujita, S.; Andica, C.; Kamagata, K.; Irie, R.; Koshino, S.; et al. Improving the Quality of Synthetic FLAIR Images with Deep Learning Using a Conditional Generative Adversarial Network for Pixel-by-Pixel Image Translation. AJNR Am. J. Neuroradiol. 2019, 40, 224–230. [Google Scholar] [CrossRef] [PubMed]
  34. Ryu, K.; Baek, H.; Cho, S.; Ha, J.; Kim, T.; Hwang, M. Clinical feasibility of 1-min ultrafast brain MRI compared with routine brain MRI using synthetic MRI: A single center pilot study. J. Neurol. 2019, 266, 431–439. [Google Scholar] [CrossRef] [PubMed]
  35. Wang, F.; Dong, Z.; Reese, T.G.; Bilgic, B.; Manhard, M.K.; Chen, J.; Polimeni, J.R.; Wald, L.L.; Setsompop, K. Echo planar time-resolved imaging (EPTI). Magn. Reson. Med. 2019, 81, 3599–3615. [Google Scholar] [CrossRef] [PubMed]
  36. Wang, F.; Dong, Z.; Reese, T.G.; Rosen, B.; Wald, L.L.; Setsompop, K. 3D Echo Planar Time-resolved Imaging (3D-EPTI) for ultrafast multi-parametric quantitative MRI. Neuroimage 2022, 250, 118963. [Google Scholar] [CrossRef]
  37. Kerleroux, B.; Kober, T.; Hilbert, T.; Serru, M.; Philippe, J.; Sirinelli, D.; Morel, B. Clinical equivalence assessment of T2 synthesized pediatric brain magnetic resonance imaging. J. Neuroradiol. 2019, 46, 130–135. [Google Scholar] [CrossRef]
  38. Gruenebach, N.; Abello Mercado, M.A.; Grauhan, N.F.; Sanner, A.; Kronfeld, A.; Groppa, S.; Schoeffling, V.I.; Hilbert, T.; Brockmann, M.A.; Othman, A.E. Clinical feasibility and validation of the accelerated T2 mapping sequence GRAPPATINI in brain imaging. Heliyon 2023, 9, e15064. [Google Scholar] [CrossRef] [PubMed]
  39. Lang, M.; Clifford, B.; Lo, W.-C.; Applewhite, B.P.; Tabari, A.; Goncalves Filho, A.L.M.; Hosseini, Z.; Longo, M.G.F.; Cauley, S.F.; Setsompop, K.; et al. Clinical Evaluation of a 2-Minute Ultrafast Brain MR Protocol for Evaluation of Acute Pathology in the Emergency and Inpatient Settings. AJNR Am. J. Neuroradiol. 2024, 45, 379–385. [Google Scholar] [CrossRef]
  40. Altmann, S.; Grauhan, N.F.; Brockstedt, L.; Kondova, M.; Schmidtmann, I.; Paul, R.; Clifford, B.; Feiweier, T.; Hosseini, Z.; Uphaus, T.; et al. Ultrafast Brain MRI with Deep Learning Reconstruction for Suspected Acute Ischemic Stroke. Radiology 2024, 310, e231938. [Google Scholar] [CrossRef]
  41. Verclytte, S.; Gnanih, R.; Verdun, S.; Feiweier, T.; Clifford, B.; Ambarki, K.; Pasquini, M.; Ding, J. Ultrafast MRI using deep learning echoplanar imaging for a comprehensive assessment of acute ischemic stroke. Eur. Radiol. 2023, 33, 3715–3725. [Google Scholar] [CrossRef]
  42. Altmann, S.; Abello Mercado, M.A.; Brockstedt, L.; Kronfeld, A.; Clifford, B.; Feiweier, T.; Uphaus, T.; Groppa, S.; Brockmann, M.A.; Othman, A.E. Ultrafast Brain MRI Protocol at 1.5 T Using Deep Learning and Multi-shot EPI. Acad. Radiol. 2023, 30, 2988–2998. [Google Scholar] [CrossRef] [PubMed]
  43. Clifford, B.; Conklin, J.; Huang, S.Y.; Feiweier, T.; Hosseini, Z.; Gonçalves Filho, A.L.M.; Tabari, A.; Demir, S.; Lo, W.-C.; Longo, M.G.F.; et al. An artificial intelligence-accelerated 2-minute multi-shot echo planar imaging protocol for comprehensive high-quality clinical brain imaging. Magn. Reson. Med. 2022, 87, 2453–2463. [Google Scholar] [CrossRef] [PubMed]
  44. Clifford, B.; Conklin, J.; Huang, S.; Feiweier, T.; Hosseini, Z.; Gonçalves Filho, A.L.M.; Tabari, A.; Demir, S.; Lo, W.-C.; Figueiro Longo, M.G.; et al. Clinical evaluation of an AI-accelerated two-minute multi-shot EPI protocol for comprehensive high-quality brain imaging. In Proceedings of the ISMRM & SMRT Annual Meeting & Exhibition, Virtual Meeting, 15–20 May 2021. [Google Scholar]
  45. Conklin, J.; Clifford, B.; Bollmann, S.; Lo, W.-C.; Bilgic, B.; Cauley, S.; Setsompop, K.; Feiweier, T.; Kirsch, J.; Gonzalez, R.; et al. A comprehensive multi-shot EPI protocol for high-quality clinical brain imaging in 3 minutes. In Proceedings of theISMRM & SMRT Annual Meeting & Exhibition, Virtual Meeting, 8–14 August 2020. [Google Scholar]
  46. Tabari, A.; Clifford, B.; Gonçalves Filho, A.L.M.; Hosseini, Z.; Feiweier, T.; Lo, W.-C.; Figueiro Longo, M.G.; Setsompop, K.; Bilgic, B.; Rapalino, O.; et al. Ultrafast Brain Imaging with Deep Learning Multi-Shot EPI: Preliminary Clinical Evaluation. MAGNETOM Flash 2021, 79, 66–70. [Google Scholar]
  47. Skare, S.; Sprenger, T.; Norbeck, O.; Rydén, H.; Blomberg, L.; Avventi, E.; Engström, M. A 1-minute full brain MR exam using a multicontrast EPI sequence. Magn. Reson. Med. 2018, 79, 3045–3054. [Google Scholar] [CrossRef]
  48. Sprenger, T.; Kits, A.; Norbeck, O.; van Niekerk, A.; Berglund, J.; Rydén, H.; Avventi, E.; Skare, S. NeuroMix—A single-scan brain exam. Magn. Reson. Med. 2021, 87, 2178–2193. [Google Scholar] [CrossRef] [PubMed]
  49. Delgado, A.F.; Kits, A.; Bystam, J.; Kaijser, M.; Skorpil, M.; Sprenger, T.; Skare, S. Diagnostic performance of a new multicontrast one-minute full brain exam (EPIMix) in neuroradiology: A prospective study. J. Magn. Reson. Imaging 2019, 50, 1824–1833. [Google Scholar] [CrossRef]
  50. Ryu, K.H.; Baek, H.; Skare, S.; Moon, J.I.; Choi, B.H.; Park, S.E.; Ha, J.Y.; Kim, T.B.; Hwang, M.; Sprenger, T. Clinical Experience of 1-Minute Brain MRI Using a Multicontrast EPI Sequence in a Different Scan Environment. AJNR Am. J. Neuroradiol. 2020, 41, 424–429. [Google Scholar] [CrossRef]
  51. Kits, A.; Luca, F.; Kolloch, J.; Müller, S.; Mazya, M.; Skare, S.; Delgado, A.F. One-Minute Multi-contrast Echo Planar Brain MRI in Ischemic Stroke: A Retrospective Observational Study of Diagnostic Performance. J. Magn. Reson. Imaging 2021, 54, 1088–1095. [Google Scholar] [CrossRef]
  52. Burén, S.; Kits, A.; Lönn, L.; Luca, F.; Sprenger, T.; Skare, S.; Delgado, A.F. A 78 Seconds Complete Brain MRI Examination in Ischemic Stroke: A Prospective Cohort Study. J. Magn. Reson. Imaging 2022, 56, 884–892. [Google Scholar] [CrossRef]
  53. Chung, M.S.; Lee, J.Y.; Jung, S.C.; Baek, S.; Shim, W.H.; Park, J.E.; Kim, H.S.; Choi, C.G.; Kim, S.J.; Lee, D.H.; et al. Reliability of fast magnetic resonance imaging for acute ischemic stroke patients using a 1.5-T scanner. Eur. Radiol. 2019, 29, 2641–2650. [Google Scholar] [CrossRef] [PubMed]
  54. Ha, J.Y.; Baek, H.J.; Ryu, K.H.; Choi, B.H.; Moon, J.I.; Park, S.E.; Kim, T.B. One-Minute Ultrafast Brain MRI with Full Basic Sequences: Can It Be a Promising Way Forward for Pediatric Neuroimaging? AJR Am. J. Roentgenol. 2020, 215, 198–205. [Google Scholar] [CrossRef]
  55. Meshksar, A.; Villablanca, J.P.; Khan, R.; Carmody, R.; Coull, B.; Nael, K. Role of EPI-FLAIR in patients with acute stroke: A comparative analysis with FLAIR. AJNR Am. J. Neuroradiol. 2014, 35, 878–883. [Google Scholar] [CrossRef] [PubMed]
  56. Nael, K.; Khan, R.; Choudhary, G.; Meshksar, A.; Villablanca, P.; Tay, J.; Drake, K.; Coull, B.M.; Kidwell, C.S. Six-minute magnetic resonance imaging protocol for evaluation of acute ischemic stroke: Pushing the boundaries. Stroke 2014, 45, 1985–1991. [Google Scholar] [CrossRef] [PubMed]
  57. Traboulsee, A.; Simon, J.H.; Stone, L.; Fisher, E.; Jones, D.E.; Malhotra, A.; Newsome, S.D.; Oh, J.; Reich, D.S.; Richert, N.; et al. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am. J. Neuroradiol. 2016, 37, 394–401. [Google Scholar] [CrossRef]
  58. Tawfik, A.I.; Kamr, W.H. Diagnostic value of 3D-FLAIR magnetic resonance sequence in detection of white matter brain lesions in multiple sclerosis. Egypt. J. Radiol. Nucl. Med. 2020, 51, 127. [Google Scholar] [CrossRef]
  59. Hammernik, K.; Schlemper, J.; Qin, C.; Duan, J.; Summers, R.M.; Rueckert, D. Σ-net: Systematic Evaluation of Iterative Deep Neural Networks for Fast Parallel MR Image Reconstruction. arXiv 2019, arXiv:1912.09278v1. [Google Scholar] [CrossRef]
  60. Uecker, M.; Lai, P.; Murphy, M.J.; Virtue, P.; Elad, M.; Pauly, J.M.; Vasanawala, S.S.; Lustig, M. ESPIRiT—An Eigenvalue Approach to Autocalibrating Parallel MRI: Where SENSE meets GRAPPA. Magn. Reson. Med. 2014, 71, 990–1001. [Google Scholar] [CrossRef]
  61. Zhang, T.; Pauly, J.M.; Vasanawala, S.S.; Lustig, M. Coil compression for accelerated imaging with Cartesian sampling. Magn. Reson. Med. 2013, 69, 571–582. [Google Scholar] [CrossRef]
  62. Demir, S.; Clifford, B.; Lo, W.-C.; Tabari, A.; Gonçalves Filho, A.L.M.; Lang, M.; Cauley, S.F.; Setsompop, K.; Bilgic, B.; Lev, M.H.; et al. Optimization of magnetization transfer contrast for EPI FLAIR brain imaging. Magn. Reson. Med. 2022, 87, 2380–2387. [Google Scholar] [CrossRef]
  63. Jezzard, P.; Balaban, R.S. Correction for geometric distortion in echo planar images from B0 field variations. Magn. Reson. Med. 1995, 34, 65–73. [Google Scholar] [CrossRef] [PubMed]
  64. Grauhan, N.F.; Grünebach, N.; Brockstedt, L.; Sanner, A.; Feiweier, T.; Schöffling, V.; Brockmann, M.A.; Othman, A.E. Reduction of Distortion Artifacts in Brain MRI Using a Field Map-based Correction Technique in Diffusion-weighted Imaging: A Prospective Study. Clin. Neuroradiol. 2024, 34, 85–91. [Google Scholar] [CrossRef]
  65. Tintoré, M.; Rovira, A.; Martínez, M.J.; Rio, J.; Díaz-Villoslada, P.; Brieva, L.; Borrás, C.; Grivé, E.; Capellades, J.; Montalban, X. Isolated demyelinating syndromes: Comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am. J. Neuroradiol. 2000, 21, 702–706. [Google Scholar] [PubMed]
  66. Bender, R.; Lange, S.; Ziegler, A. Multiples Testen. Dtsch. Med. Wochenschr. 2007, 132, e26–e29. [Google Scholar] [CrossRef]
  67. Noyes, K.; Weinstock-Guttman, B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am. J. Manag. Care 2013, 19, s321–s331. [Google Scholar]
  68. Cohan, S.; Chen, C.; Baraban, E.; Stuchiner, T.; Grote, L. MRI utility in the detection of disease activity in clinically stable patients with multiple sclerosis: A retrospective analysis of a community based cohort. BMC Neurol. 2016, 16, 184. [Google Scholar] [CrossRef]
  69. Eran, A.; García, M.; Malouf, R.; Bosak, N.; Wagner, R.; Ganelin-Cohen, E.; Artsy, E.; Shifrin, A.; Rozenberg, A. MRI in predicting conversion to multiple sclerosis within 1 year. Brain Behav. 2018, 8, e01042. [Google Scholar] [CrossRef]
  70. Sutherland, G.; Russell, N.; Gibbard, R.; Dobrescu, A. The Value of Radiology, Part II; The Conference Board of Canada: Ottawa, ON, Canada, 2019. [Google Scholar]
  71. van Nynatten, L.; Gershon, A. Radiology wait times: Impact on Patient Care and Potential Solutions. Univ. West. Ont. Med. J. 2017, 86, 65–66. [Google Scholar] [CrossRef]
  72. van Sambeek, J.R.; Joustra, P.E.; Das, S.F.; Bakker, P.J.; Maas, M. Reducing MRI access times by tackling the appointment-scheduling strategy. BMJ Qual. Saf. 2011, 20, 1075–1080. [Google Scholar] [CrossRef]
  73. Nuti, S.; Vainieri, M. Managing waiting times in diagnostic medical imaging. BMJ Open 2012, 2, e001255. [Google Scholar] [CrossRef]
  74. Biloglav, Z.; Medaković, P.; Buljević, J.; Žuvela, F.; Padjen, I.; Vrkić, D.; Ćurić, J. The analysis of waiting time and utilization of computed tomography and magnetic resonance imaging in Croatia: A nationwide survey. Croat. Med. J. 2020, 61, 538–546. [Google Scholar] [CrossRef] [PubMed]
  75. Boldor, N.; Vaknin, S.; Myers, V.; Hakak, N.; Somekh, M.; Wilf-Miron, R.; Luxenburg, O. Reforming the MRI system: The Israeli National Program to shorten waiting times and increase efficiency. Isr. J. Health Policy Res. 2021, 10, 57. [Google Scholar] [CrossRef] [PubMed]
  76. Henkelman, R.M.; Stanisz, G.J.; Graham, S.J. Magnetization transfer in MRI: A review. NMR Biomed. 2001, 14, 57–64. [Google Scholar] [CrossRef] [PubMed]
  77. Deshmane, A.; Gulani, V.; Griswold, M.A.; Seiberlich, N. Parallel MR imaging. J. Magn. Reson. Imaging 2012, 36, 55–72. [Google Scholar] [CrossRef] [PubMed]
  78. Aja-Fernández, S.; Vegas-Sánchez-Ferrero, G.; Tristán-Vega, A. Noise estimation in parallel MRI: GRAPPA and SENSE. Magn. Reson. Imaging 2014, 32, 281–290. [Google Scholar] [CrossRef]
  79. Breuer, F.A.; Kannengiesser, S.A.; Blaimer, M.; Seiberlich, N.; Jakob, P.M.; Griswold, M.A. General formulation for quantitative G-factor calculation in GRAPPA reconstructions. Magn. Reson. Med. 2009, 62, 739–746. [Google Scholar] [CrossRef]
  80. Bernstein, M.A.; King, K.F.; Zhou, X.J. Handbook of MRI Pulse Sequences; Elsevier Academic Press: Amsterdam, The Netherlands, 2004; pp. 732–734. ISBN 978-0-12-092861-3. [Google Scholar]
  81. Schenck, J.F. The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. Med. Phys. 1996, 23, 815–850. [Google Scholar] [CrossRef]
  82. Phalke, V.V.; Gujar, S.; Quint, D.J. Comparison of 3.0 T versus 1.5 T MR: Imaging of the spine. Neuroimaging Clin. N. Am. 2006, 16, 241–248. [Google Scholar] [CrossRef] [PubMed]
  83. Alvarez-Linera, J. 3T MRI: Advances in brain imaging. Eur. J. Radiol. 2008, 67, 415–426. [Google Scholar] [CrossRef]
  84. Stadler, A.; Schima, W.; Ba-Ssalamah, A.; Kettenbach, J.; Eisenhuber, E. Artifacts in body MR imaging: Their appearance and how to eliminate them. Eur. Radiol. 2007, 17, 1242–1255. [Google Scholar] [CrossRef]
  85. Arena, L.; Morehouse, H.T.; Safir, J. MR imaging artifacts that simulate disease: How to recognize and eliminate them. Radiographics 1995, 15, 1373–1394. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Flowchart of study participants. Note. MRI = magnetic resonance imaging; MS = multiple sclerosis.
Figure 1. Flowchart of study participants. Note. MRI = magnetic resonance imaging; MS = multiple sclerosis.
Diagnostics 14 01841 g001
Figure 2. Classification of TPGS lesions. Note. TPGS lesions = total number of true-positive lesions detected using all contrasts available (gold standard); FLAIR3Da = axial reconstruction of FLAIR3D; FLAIRUF = ultrafast axial FLAIR; tseTPGS = subset of TPGS recorded with FLAIRTSE; FLAIRTSE = axial standard TSE-FLAIR; GS = utilization of all contrasts available, particularly T2-FLAIR, T1, and T2; TP = true-positives; FN = false-negatives; 1 = better/larger in the FLAIRUF images compared to FLAIR3Da; 2 = equal compared to FLAIR3Da; 3 = better in the FLAIR3Da images, but classified as a lesion using only the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not at all visible in the FLAIRUF images; PV = periventricular; (J-)C = (juxta-)cortical; I = infratentorial (brainstem, cerebellum); F = frontal; P = parietal; T = temporal; O = occipital; C = central (insular lobe, corpus callosum, basal nuclei, diencephalon).
Figure 2. Classification of TPGS lesions. Note. TPGS lesions = total number of true-positive lesions detected using all contrasts available (gold standard); FLAIR3Da = axial reconstruction of FLAIR3D; FLAIRUF = ultrafast axial FLAIR; tseTPGS = subset of TPGS recorded with FLAIRTSE; FLAIRTSE = axial standard TSE-FLAIR; GS = utilization of all contrasts available, particularly T2-FLAIR, T1, and T2; TP = true-positives; FN = false-negatives; 1 = better/larger in the FLAIRUF images compared to FLAIR3Da; 2 = equal compared to FLAIR3Da; 3 = better in the FLAIR3Da images, but classified as a lesion using only the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not at all visible in the FLAIRUF images; PV = periventricular; (J-)C = (juxta-)cortical; I = infratentorial (brainstem, cerebellum); F = frontal; P = parietal; T = temporal; O = occipital; C = central (insular lobe, corpus callosum, basal nuclei, diencephalon).
Diagnostics 14 01841 g002
Figure 3. Classification of FP lesions. Note. FP = false-positive; further abbreviations as in Figure 2.
Figure 3. Classification of FP lesions. Note. FP = false-positive; further abbreviations as in Figure 2.
Diagnostics 14 01841 g003
Figure 4. Correlations between TPUF, FNUF, TP3Da, FN3Da, and TPGS lesion counts. Schematic illustration (a) and contingency table (b). Note. TPGS = number of true-positive lesions detected using all contrasts available (gold standard); TPUF = true-positive lesions detected in the FLAIRUF images; FNUF = false-negative lesions using the FLAIRUF images; TP3Da = true-positive lesions detected in the FLAIR3Da images; FN3Da = false-negative lesions using the FLAIR3Da images.
Figure 4. Correlations between TPUF, FNUF, TP3Da, FN3Da, and TPGS lesion counts. Schematic illustration (a) and contingency table (b). Note. TPGS = number of true-positive lesions detected using all contrasts available (gold standard); TPUF = true-positive lesions detected in the FLAIRUF images; FNUF = false-negative lesions using the FLAIRUF images; TP3Da = true-positive lesions detected in the FLAIR3Da images; FN3Da = false-negative lesions using the FLAIR3Da images.
Diagnostics 14 01841 g004
Figure 5. Contingency tables correlating TPUF, FNUF, TP3Da, FN3Da, and TPGS lesion counts, grouped by size, according to Figure 4. Note. Abbreviations as in Figure 4. 1 191 of them were ‘characteristic MS lesions’, including 109 periventricular lesions, 44 infratentorial lesions, and 38 (juxta-)cortical lesions.
Figure 5. Contingency tables correlating TPUF, FNUF, TP3Da, FN3Da, and TPGS lesion counts, grouped by size, according to Figure 4. Note. Abbreviations as in Figure 4. 1 191 of them were ‘characteristic MS lesions’, including 109 periventricular lesions, 44 infratentorial lesions, and 38 (juxta-)cortical lesions.
Diagnostics 14 01841 g005
Figure 6. Sensitivity and PPV in terms of lesion detection, using FLAIRUF images (gray) and FLAIR3Da images (white). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs: (a) For wide lesions, no significant difference in sensitivity could be found. For the groups that comprise smaller lesions, however, the sensitivity was significantly inferior using the FLAIRUF images, decreasing more and more as a function of lesion diameter. (b) No significant differences in PPV were found for any of the large lesion groups (large, wide, and narrow). For small lesions, the PPV in the FLAIRUF images was moderately lower compared to the FLAIR3Da group (no overlap between confidence intervals). Note. Abbreviations as in Table 3. * p < 0.05.
Figure 6. Sensitivity and PPV in terms of lesion detection, using FLAIRUF images (gray) and FLAIR3Da images (white). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs: (a) For wide lesions, no significant difference in sensitivity could be found. For the groups that comprise smaller lesions, however, the sensitivity was significantly inferior using the FLAIRUF images, decreasing more and more as a function of lesion diameter. (b) No significant differences in PPV were found for any of the large lesion groups (large, wide, and narrow). For small lesions, the PPV in the FLAIRUF images was moderately lower compared to the FLAIR3Da group (no overlap between confidence intervals). Note. Abbreviations as in Table 3. * p < 0.05.
Diagnostics 14 01841 g006
Figure 7. FNUF lesions (top row) contrasted with their TP3Da counterparts (arrow, bottom row). The images also show several other lesions: (a) Lesion in the splenium of the corpus callosum (approx. 3 mm × 2 mm). Causes for it not being detected may be image noise and slice thickness/slice gaps. (b) Left frontal lesion (approx. 3 mm × 1 mm). Causes may be associated with slice thickness/contrast as well as image noise. (c) Thin right frontal lesion (approx. 7 mm × 1 mm). It was mistaken for cortex in the FLAIRUF image. (d) Left temporopolar lesion (approx. 3 mm × 2 mm). It was not recognized as such in the FLAIRUF image owing to commonly occurring distortions within this region. Note. Corresponding slices could not be positioned exactly identically for two reasons: Different slice thicknesses including slice gaps (c) and non-parallel slice inclinations (d).
Figure 7. FNUF lesions (top row) contrasted with their TP3Da counterparts (arrow, bottom row). The images also show several other lesions: (a) Lesion in the splenium of the corpus callosum (approx. 3 mm × 2 mm). Causes for it not being detected may be image noise and slice thickness/slice gaps. (b) Left frontal lesion (approx. 3 mm × 1 mm). Causes may be associated with slice thickness/contrast as well as image noise. (c) Thin right frontal lesion (approx. 7 mm × 1 mm). It was mistaken for cortex in the FLAIRUF image. (d) Left temporopolar lesion (approx. 3 mm × 2 mm). It was not recognized as such in the FLAIRUF image owing to commonly occurring distortions within this region. Note. Corresponding slices could not be positioned exactly identically for two reasons: Different slice thicknesses including slice gaps (c) and non-parallel slice inclinations (d).
Diagnostics 14 01841 g007
Figure 8. Correlations between tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesion counts. Schematic illustration (a) and contingency table (b). Note. TPGS = number of true-positive lesions detected using all contrasts available (gold standard); tseTPGS = subset of TPGS recorded with FLAIRTSE; tseTPUF = corresponding subset of TPUF recorded with FLAIRTSE; tseFNUF = corresponding subset of FNUF recorded with FLAIRTSE; TPTSE = true-positive lesions detected in the FLAIRTSE images; FNTSE = false-negative lesions using the FLAIRTSE images; further abbreviations as in Figure 4.
Figure 8. Correlations between tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesion counts. Schematic illustration (a) and contingency table (b). Note. TPGS = number of true-positive lesions detected using all contrasts available (gold standard); tseTPGS = subset of TPGS recorded with FLAIRTSE; tseTPUF = corresponding subset of TPUF recorded with FLAIRTSE; tseFNUF = corresponding subset of FNUF recorded with FLAIRTSE; TPTSE = true-positive lesions detected in the FLAIRTSE images; FNTSE = false-negative lesions using the FLAIRTSE images; further abbreviations as in Figure 4.
Diagnostics 14 01841 g008
Figure 9. Contingency tables including a subset of those TPGS lesions covered by the FLAIRTSE sequence (tseTPGS). tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesion counts are correlated, and grouped by size, according to Figure 8. Note. Abbreviations as in Figure 8. 1 One was FN using FLAIR3Da; the rest were TP in FLAIR3Da. 2 Two were FN using FLAIR3Da; the rest were TP in FLAIR3Da. 3 Three were FN using FLAIR3Da; the rest were TP in FLAIR3Da. 4 Four were FN using FLAIR3Da; the rest were TP in FLAIR3Da. Lesion counts without superscripts were all TP in FLAIR3Da.
Figure 9. Contingency tables including a subset of those TPGS lesions covered by the FLAIRTSE sequence (tseTPGS). tseTPUF, tseFNUF, TPTSE, FNTSE, and tseTPGS lesion counts are correlated, and grouped by size, according to Figure 8. Note. Abbreviations as in Figure 8. 1 One was FN using FLAIR3Da; the rest were TP in FLAIR3Da. 2 Two were FN using FLAIR3Da; the rest were TP in FLAIR3Da. 3 Three were FN using FLAIR3Da; the rest were TP in FLAIR3Da. 4 Four were FN using FLAIR3Da; the rest were TP in FLAIR3Da. Lesion counts without superscripts were all TP in FLAIR3Da.
Diagnostics 14 01841 g009
Figure 10. An MS patient received an MRI scan including three T2w FLAIR sequences: FLAIRUF (a), FLAIRTSE (b), and FLAIR3D (c). Five lesions can be seen in each picture, situated in the frontoparietal region.
Figure 10. An MS patient received an MRI scan including three T2w FLAIR sequences: FLAIRUF (a), FLAIRTSE (b), and FLAIR3D (c). Five lesions can be seen in each picture, situated in the frontoparietal region.
Diagnostics 14 01841 g010
Figure 11. Sensitivity in terms of lesion detection, using FLAIRTSE images (white) and corresponding FLAIRUF images (gray). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs. No significant differences in sensitivity could be detected for any of the lesion groups (p > 0.05). For small lesions, however, the data suggest a lower sensitivity using the FLAIRUF images compared to the FLAIRTSE images. Results imply that there is a correlation between lesion detectability and size in both cases, though. Note. Abbreviations as in Table 7.
Figure 11. Sensitivity in terms of lesion detection, using FLAIRTSE images (white) and corresponding FLAIRUF images (gray). Four groups, which represent different lesion diameters, are displayed, respectively. The additional error bars denote the 95% CIs. No significant differences in sensitivity could be detected for any of the lesion groups (p > 0.05). For small lesions, however, the data suggest a lower sensitivity using the FLAIRUF images compared to the FLAIRTSE images. Results imply that there is a correlation between lesion detectability and size in both cases, though. Note. Abbreviations as in Table 7.
Diagnostics 14 01841 g011
Figure 12. Conspicuity ratings of lesions in the FLAIRUF images, categorized by size and location. Lesion conspicuity was significantly superior for large lesions compared to small lesions. Unless for small lesions, there was a significant difference among some brain regions for large lesions. This could be attributed to occipital lesions (superior) and central lesions (inferior). Note. Black = 1; dark gray = 2; gray = 3; light gray = 4; white = 5. Abbreviations and brain regions as in Table 11. * p < 0.05.
Figure 12. Conspicuity ratings of lesions in the FLAIRUF images, categorized by size and location. Lesion conspicuity was significantly superior for large lesions compared to small lesions. Unless for small lesions, there was a significant difference among some brain regions for large lesions. This could be attributed to occipital lesions (superior) and central lesions (inferior). Note. Black = 1; dark gray = 2; gray = 3; light gray = 4; white = 5. Abbreviations and brain regions as in Table 11. * p < 0.05.
Diagnostics 14 01841 g012
Figure 13. SNR and CNR in FLAIRUF images (top) and FLAIR3Da images (bottom): (a) Inflammatory lesions. Continuous arrow: Large lesion in the right mesencephalon (approx. 8 mm × 6 mm). The SNR appeared reduced in the center of the FLAIRUF image, thus decreasing the lesion conspicuity. Dotted arrows: Temporal lesions (right: approx. 5 mm × 4 mm; left: approx. 4 mm × 3 mm). The SNR appeared significantly improved in posterior brain regions in the FLAIRUF images, thus equaling lesion conspicuity between the image variants. Note that in FLAIR3Da, the left lesion was better visible in the adjacent image slice (not depicted). Arrowhead: Partially imaged, right temporal lesion (approx. 3 mm × 1 mm in the slice image depicted). Comparison of adjacent slice images showed equal lesion conspicuity. (b) Arrow: Left frontal lesion (approx. 2 mm × 1 mm). Excellent lesion conspicuity in the FLAIRUF image due to very good SNR and CNR. (c) Infratentorial lesions. Continuous arrow: Large lesion (approx. 9 mm × 6 mm) that was not visible in the FLAIRUF image owing to low SNR and CNR. Dotted arrow: Large lesion (approx. 8 mm × 6 mm) that was less visible in the FLAIRUF image due to reduced SNR and CNR. Arrowhead: Large lesion (approx. 3 mm × 2 mm) that was better visible in the FLAIRUF image. Note that the SNR improves toward the outer regions of the FLAIRUF image.
Figure 13. SNR and CNR in FLAIRUF images (top) and FLAIR3Da images (bottom): (a) Inflammatory lesions. Continuous arrow: Large lesion in the right mesencephalon (approx. 8 mm × 6 mm). The SNR appeared reduced in the center of the FLAIRUF image, thus decreasing the lesion conspicuity. Dotted arrows: Temporal lesions (right: approx. 5 mm × 4 mm; left: approx. 4 mm × 3 mm). The SNR appeared significantly improved in posterior brain regions in the FLAIRUF images, thus equaling lesion conspicuity between the image variants. Note that in FLAIR3Da, the left lesion was better visible in the adjacent image slice (not depicted). Arrowhead: Partially imaged, right temporal lesion (approx. 3 mm × 1 mm in the slice image depicted). Comparison of adjacent slice images showed equal lesion conspicuity. (b) Arrow: Left frontal lesion (approx. 2 mm × 1 mm). Excellent lesion conspicuity in the FLAIRUF image due to very good SNR and CNR. (c) Infratentorial lesions. Continuous arrow: Large lesion (approx. 9 mm × 6 mm) that was not visible in the FLAIRUF image owing to low SNR and CNR. Dotted arrow: Large lesion (approx. 8 mm × 6 mm) that was less visible in the FLAIRUF image due to reduced SNR and CNR. Arrowhead: Large lesion (approx. 3 mm × 2 mm) that was better visible in the FLAIRUF image. Note that the SNR improves toward the outer regions of the FLAIRUF image.
Diagnostics 14 01841 g013
Figure 14. Spatial distortion artifacts in the FLAIRUF images: (a) Frontal distortion artifact limiting the diagnostic information in that region. (b) Frontobasal distortion artifacts resulting in limited diagnostic information from that region. (c) Temporopolar distortion artifacts limiting the diagnostic information in the vicinity. In contrast, the cerebellar and pontine distortion artifacts do not limit diagnostic information.
Figure 14. Spatial distortion artifacts in the FLAIRUF images: (a) Frontal distortion artifact limiting the diagnostic information in that region. (b) Frontobasal distortion artifacts resulting in limited diagnostic information from that region. (c) Temporopolar distortion artifacts limiting the diagnostic information in the vicinity. In contrast, the cerebellar and pontine distortion artifacts do not limit diagnostic information.
Diagnostics 14 01841 g014
Figure 15. Infratentorial pulsatile flow artifacts that severely limit diagnostic information in the FLAIRUF images and the FLAIR3Da images: (a) FLAIRUF (left) and FLAIR3Da as a reference (right), cerebellum: The continuous arrows depict an inflammatory true-positive lesion (approx. 4 mm × 3 mm). The dotted arrow indicates a pulsation artifact that is prone to being confused with a lesion. It was counted as a small, false-positive lesion (approx. 2 mm × 1 mm). The arrowhead points to a pulsation artifact that is not likely to be confused with a lesion due to its typical location adjacent to the occipital sinus. (b) FLAIR3Da (left) and FLAIRUF as a reference (right), at the level of the pons: Top images: Typical hyperintense artifact band in the FLAIR3Da image; the arrowhead points to an intensely hyperintense spot within the artifact region that is part of the grainy texture of the artifact. Possible lesions within the artifact region would have been masked completely. Middle images: the continuous arrows show a large lesion (approx. 8 mm × 3 mm) that was misinterpreted as part of the pulsation artifact in the FLAIR3Da image. Bottom images: The dotted arrow denotes a small, false-positive FLAIR3Da lesion (approx. 2 mm × 2 mm) that turned out to be part of the pulsation artifact. Note. Corresponding slices could not be positioned exactly identically owing to different slice thicknesses including slice gaps and non-parallel slice inclinations.
Figure 15. Infratentorial pulsatile flow artifacts that severely limit diagnostic information in the FLAIRUF images and the FLAIR3Da images: (a) FLAIRUF (left) and FLAIR3Da as a reference (right), cerebellum: The continuous arrows depict an inflammatory true-positive lesion (approx. 4 mm × 3 mm). The dotted arrow indicates a pulsation artifact that is prone to being confused with a lesion. It was counted as a small, false-positive lesion (approx. 2 mm × 1 mm). The arrowhead points to a pulsation artifact that is not likely to be confused with a lesion due to its typical location adjacent to the occipital sinus. (b) FLAIR3Da (left) and FLAIRUF as a reference (right), at the level of the pons: Top images: Typical hyperintense artifact band in the FLAIR3Da image; the arrowhead points to an intensely hyperintense spot within the artifact region that is part of the grainy texture of the artifact. Possible lesions within the artifact region would have been masked completely. Middle images: the continuous arrows show a large lesion (approx. 8 mm × 3 mm) that was misinterpreted as part of the pulsation artifact in the FLAIR3Da image. Bottom images: The dotted arrow denotes a small, false-positive FLAIR3Da lesion (approx. 2 mm × 2 mm) that turned out to be part of the pulsation artifact. Note. Corresponding slices could not be positioned exactly identically owing to different slice thicknesses including slice gaps and non-parallel slice inclinations.
Diagnostics 14 01841 g015
Figure 16. Minor artifacts in the FLAIRUF images: (a) Supratentorial pulsation artifacts, caused by extracerebral blood vessels: hyperintense (left image) or hypointense (right image). Hyperintense artifacts can usually be distinguished easily from a lesion, owing to its well-defined, sharply demarcated margin in relation to its size. Hyperintense and hypointense artifacts can usually be related to distant blood vessels, shifted along the phase encoding direction at fixed intervals corresponding to k-space sampling patterns (a quarter of the field of view for the protocol used in our study). Hyperintense artifacts are often located directly adjacent to hypointense artifacts in neighboring image slices. (b) Rare chemical shift artifacts due to incomplete fat suppression, in the shape of hyperintense (left image) or hypointense (right image) frontal streaks. (c) Rare residual aliasing, in the shape of a subtle hyperintense right central streak. (d) Rare spike artifacts, appearing in a herringbone pattern. (e) Supratentorial pulsation artifacts, caused by parenchymal blood vessels (singular findings): hyperintense (small FP lesion), insular cortex (left image), and hypointense, anterior limb of internal capsule (right image). They could not be distinguished using the FLAIR3D sequence, however, were clearly correlated with contrast-enhanced images. Also, note the ventricular cerebrospinal fluid pulsation artifact in the right image.
Figure 16. Minor artifacts in the FLAIRUF images: (a) Supratentorial pulsation artifacts, caused by extracerebral blood vessels: hyperintense (left image) or hypointense (right image). Hyperintense artifacts can usually be distinguished easily from a lesion, owing to its well-defined, sharply demarcated margin in relation to its size. Hyperintense and hypointense artifacts can usually be related to distant blood vessels, shifted along the phase encoding direction at fixed intervals corresponding to k-space sampling patterns (a quarter of the field of view for the protocol used in our study). Hyperintense artifacts are often located directly adjacent to hypointense artifacts in neighboring image slices. (b) Rare chemical shift artifacts due to incomplete fat suppression, in the shape of hyperintense (left image) or hypointense (right image) frontal streaks. (c) Rare residual aliasing, in the shape of a subtle hyperintense right central streak. (d) Rare spike artifacts, appearing in a herringbone pattern. (e) Supratentorial pulsation artifacts, caused by parenchymal blood vessels (singular findings): hyperintense (small FP lesion), insular cortex (left image), and hypointense, anterior limb of internal capsule (right image). They could not be distinguished using the FLAIR3D sequence, however, were clearly correlated with contrast-enhanced images. Also, note the ventricular cerebrospinal fluid pulsation artifact in the right image.
Diagnostics 14 01841 g016
Figure 17. Infratentorial pulsatile flow artifacts in FLAIRTSE (left), contrasted with corresponding FLAIRUF slices (right). The artifact regions are marked with dotted arrows. They appear as irregular, streaky bands traversing the cerebellum from the right sigmoid sinus to the left sigmoid sinus: (a) Artifact-induced hyper- and hypointense dots across the cerebellum; the FLAIRUF image confirms that there is no actual lesion in this area. (b) Artifact-induced hyper- and hypointense streaks across the cerebellum; the FLAIRUF image confirms that there is one actual lesion (continuous arrow) in this area. Note. Corresponding slices could not be positioned exactly identically owing to different slice intervals and non-parallel slice inclinations.
Figure 17. Infratentorial pulsatile flow artifacts in FLAIRTSE (left), contrasted with corresponding FLAIRUF slices (right). The artifact regions are marked with dotted arrows. They appear as irregular, streaky bands traversing the cerebellum from the right sigmoid sinus to the left sigmoid sinus: (a) Artifact-induced hyper- and hypointense dots across the cerebellum; the FLAIRUF image confirms that there is no actual lesion in this area. (b) Artifact-induced hyper- and hypointense streaks across the cerebellum; the FLAIRUF image confirms that there is one actual lesion (continuous arrow) in this area. Note. Corresponding slices could not be positioned exactly identically owing to different slice intervals and non-parallel slice inclinations.
Diagnostics 14 01841 g017
Figure 18. Positional dependence of SNR and CNR within the FLAIRUF images: (a) Image slice at the level of the basal nuclei. The SNR deteriorates toward the center of the image, whereas the CNR remains relatively good. Note that both the SNR and CNR are excellent in the marginal regions of the cerebral cortex, e.g., in the occipital lobe. (b) Image slice at the level of the pons and the cerebellum. The SNR is substandard around the pons and improves exceedingly toward the posterior lobe of the cerebellum to an excellent level. The CNR, however, seems generally slightly substandard in this area compared to other brain regions, even in the most posterior regions. This may be associated with the characteristic, fine folium-sulcus texture of the cerebellum (e.g., vermis or posterior lobe), which cannot be distinguished clearly.
Figure 18. Positional dependence of SNR and CNR within the FLAIRUF images: (a) Image slice at the level of the basal nuclei. The SNR deteriorates toward the center of the image, whereas the CNR remains relatively good. Note that both the SNR and CNR are excellent in the marginal regions of the cerebral cortex, e.g., in the occipital lobe. (b) Image slice at the level of the pons and the cerebellum. The SNR is substandard around the pons and improves exceedingly toward the posterior lobe of the cerebellum to an excellent level. The CNR, however, seems generally slightly substandard in this area compared to other brain regions, even in the most posterior regions. This may be associated with the characteristic, fine folium-sulcus texture of the cerebellum (e.g., vermis or posterior lobe), which cannot be distinguished clearly.
Diagnostics 14 01841 g018
Table 1. Patient characteristics.
Table 1. Patient characteristics.
CharacteristicsValues
Number of patients17
Mean age ± standard deviation33 ± 10 years
Median age (range)29 (21–60) years
Distribution between sexes71% male (n = 12), 29% female (n = 5)
Note. One patient underwent a second follow-up MRI examination six months later during the investigation period and is included twice. Years and percentages are rounded to the whole numbers.
Table 2. MRI acquisition parameters.
Table 2. MRI acquisition parameters.
ParameterFLAIRUFFLAIRTSEFLAIR3D
OrientationAxialAxial-
Sequence typeMulti-shot EPITSESPACE
TR (ms)800088005000
TE (ms)8887386
TI (ms)237224801800
Flip angle (°)180150120 (VFA)
Voxel size (mm)0.9 × 0.9 × 40.7 × 0.7 × 40.5 × 0.5 × 0.9 1
Gap between slices (mm)0.80-
Phase encoding directionP → AR → LA → P
Acceleration modeDL-basedGRAPPAGRAPPA
Acceleration factor222
In-plane FOV (read × phase; mm)230 × 230230 × 187256 × 256 1
Number of slices3236192
Time of acquisition (min:s)0:512:224:57
Note. FLAIR = fluid-attenuated inversion recovery; FLAIRUF = ultrafast FLAIR sequence; FLAIRTSE = turbo/fast spin-echo FLAIR sequence; FLAIR3D = three-dimensional FLAIR sequence; TR = repetition time; TE = echo time; TI = inversion time; FOV = field-of-view; EPI = echo-planar-imaging; TSE = turbo/fast spin echo; SPACE = sampling perfection with application-optimized contrasts using different flip angle evolution; VFA = variable flip angles; A = anterior; P = posterior; R = right; L = left; DL = deep learning; GRAPPA = generalized autocalibrating partial parallel acquisition. 1 Values refer to the sagittal orientation. Slice thickness of the axially reconstructed images used for side-by-side comparisons (FLAIR3Da) = 3 mm.
Table 3. Lesion detection in FLAIRUF images and FLAIR3Da images.
Table 3. Lesion detection in FLAIRUF images and FLAIR3Da images.
Total SensitivityPPV
Lesion SizeSTPFNTPGSFP95% CI [LL, UL]p95% CI [LL, UL]
nnnn% %
Large
(≥3 mm)
UF251372881187.2 [82.7, 90.8]<0.00195.8 [92.6, 97.9]
3Da274141195.1 [92.0, 97.3]96.1 [93.2, 98.1]
 Wide
 (×≥2 mm)
UF16011171693.6 [88.8, 96.7]0.5096.4 [92.3, 98.7]
3Da1638895.3 [91.0, 98.0]95.3 [91.0, 98.0]
 Narrow
 (×<2 mm)
UF9126117577.8 [69.2, 84.9]<0.00194.8 [88.3, 98.3]
3Da1116394.9 [89.2, 98.1]97.4 [92.5, 99.5]
Small
(<3 mm)
UF1481322803352.9 [46.8, 58.8]<0.00181.8 [75.4, 87.1]
3Da268121595.7 [92.6, 97.8]94.7 [91.4, 97.0]
Note. S = sequence; UF = FLAIRUF; 3Da = FLAIR3Da; PPV = positive predictive value; CI = confidence interval (Clopper–Pearson); LL = lower limit; UL = upper limit; further abbreviations as in Figure 2, Figure 3 and Figure 4. To compare sensitivity results (or, more precisely, to compare the FNUF and TP3Da lesion counts with the FN3Da and TPUF lesion counts) McNemar’s test was performed, based on paired data shown in Figure 5. To compare PPV results, no statistical test was performed, since data were neither completely paired nor completely independent samples.
Table 4. Presumed causes of FN large lesions (≥3 mm total) in FLAIRUF and FLAIR3Da images.
Table 4. Presumed causes of FN large lesions (≥3 mm total) in FLAIRUF and FLAIR3Da images.
FLAIRUFFLAIR3Da
Presumed Type of CauseFNUF
Total
FNUF and
TP3Da
FNUF and
FN3Da
FN3Da and
TPUF
FN3Da
Total
nnnnnn
Not detectableSR/CNR/SNR 228226011
Mistaken for natural structure 1743303
Mistaken for/masked by pulsation artifact0007 33 310 3
Masked by distortion artifact211000
Total372710414
Note. SR = spatial resolution, esp. slice thickness; CNR = contrast-to-noise ratio; SNR = signal-to-noise ratio; further abbreviations as in Figure 2 and Figure 4. 1 Cortex, in particular. 2 Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases. 3 All lesions were located in an infratentorial position.
Table 5. Presumed causes of FN small lesions (<3 mm) in FLAIRUF and FLAIR3Da images.
Table 5. Presumed causes of FN small lesions (<3 mm) in FLAIRUF and FLAIR3Da images.
FLAIRUFFLAIR3Da
Presumed Type of CauseFNUF
Total
FNUF and
TP3Da
FNUF and
FN3Da
FN3Da and
TPUF
FN3Da
Total
nnnnnn
Not detectableSR/CNR/SNR 21101055033
Mistaken for natural structure 121192314
Mistaken for/masked by pulsation artifact0005 305 3
Masked by distortion artifact101000
Total1321248412
Note. Abbreviations as in Table 4. 1 Cortex, in particular. 2 Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases. 3 Three were located in an infratentorial position; the rest were located in a supratentorial position.
Table 6. Presumed causes of FP lesions in FLAIRUF and FLAIR3Da images.
Table 6. Presumed causes of FP lesions in FLAIRUF and FLAIR3Da images.
FLAIRUFFLAIR3Da
Presumed Causal PhenomenonFPUF
Large
(≥3 mm)
FPUF
Small
(<3 mm)
FPUF
Total
FP3Da
Large
(≥3 mm)
FP3Da
Small
(<3 mm)
FP3Da
Total
nnnnnn
Partially imaged natural structure 1SR 2924336713
Partially imaged nearby large lesion022011
Pulsation artifact2 37 39 35 47 512 5
Total113344111526
Note. SR = spatial resolution, esp. slice thickness; FPUF = false-positive lesions using the FLAIRUF images; FP3Da = false-positive lesions using the FLAIR3Da images. 1 Cortex, in particular. 2 CNR and SNR are also partly involved. 3 One was located in a supratentorial position; the rest were located in an infratentorial position. 4 All lesions were located in an infratentorial position. 5 Three were located in a supratentorial position; the rest were located in an infratentorial position.
Table 7. Lesion detectability in FLAIRTSE images and FLAIRUF counterparts.
Table 7. Lesion detectability in FLAIRTSE images and FLAIRUF counterparts.
Total Sensitivity
Lesion SizeStseTPtseFNtseTPGS95% CI [LL, UL]p
nnn%
Large
(≥3 mm)
UF4855390.6 [79.3, 96.9]0.68
TSE48590.6 [79.3, 96.9]
 Wide
 (×≥2 mm)
UF3323594.3 [80.8, 99.3]>0.99
TSE34197.1 [85.1, 99.9]
 Narrow
 (×<2 mm)
UF1531883.3 [58.6, 96.4]>0.99
TSE14477.8 [52.4, 93.6]
Small
(<3 mm)
UF19153455.9 [37.9, 72.8]0.08
TSE27779.4 [62.1, 91.3]
Note. TSE = FLAIRTSE; further abbreviations as in Table 3 and Figure 8. To compare sensitivity results, McNemar’s test was performed, based on paired data shown in Figure 9. Unlike in the previous Section, the corresponding FP values (see Table 10) were insufficient to ensure reliable PPV analysis results; hence, it was omitted here.
Table 8. Presumed causes of FN large lesions (≥3 mm total) in FLAIRTSE and corresponding FLAIRTSE images.
Table 8. Presumed causes of FN large lesions (≥3 mm total) in FLAIRTSE and corresponding FLAIRTSE images.
FLAIRUFFLAIRTSE
Presumed Type of CausetseFNUF
Total
tseFNUF and
TPTSE
tseFNUF and FNTSEFNTSE and
tseTPUF
FNTSE
Total
nnnnnn
Not detectableSR/CNR/SNR 2330033
Mistaken for natural structure 1202202
Total53235
Note. Abbreviations as in Table 4 and Figure 8. 1 Cortex, in particular. 2 Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases.
Table 9. Presumed causes of FN small lesions (<3 mm) in FLAIRTSE and corresponding FLAIRTSE images.
Table 9. Presumed causes of FN small lesions (<3 mm) in FLAIRTSE and corresponding FLAIRTSE images.
FLAIRUFFLAIRTSE
Presumed Type of CausetseFNUF
Total
tseFNUF and
TPTSE
tseFNUF and FNTSEFNTSE and
tseTPUF
FNTSE
Total
nnnnnn
Not detectableSR/CNR/SNR 213103336
Mistaken for natural structure 1220011
Total1512347
Note. Abbreviations as in Table 4 and Figure 8. 1 Cortex, in particular. 2 Causes of SR, CNR, and SNR could not strictly be distinguished. It is likely that there is a combination of those causes in most cases.
Table 10. Presumed causes of FP lesions in FLAIRUF and FLAIRTSE images.
Table 10. Presumed causes of FP lesions in FLAIRUF and FLAIRTSE images.
FLAIRUFFLAIRTSE
Presumed Causal PhenomenontseFPUF
Large
(≥3 mm)
tseFPUF
Small
(<3 mm)
tseFPUF
Total
FPTSE
Large
(≥3 mm)
FPTSE
Small
(<3 mm)
FPTSE
Total
nnnnnn
Partially imaged natural structure 1SR 2112134
Partially imaged nearby large lesion011011
Total123145
Note. SR = spatial resolution, esp. slice thickness; FPTSE = false-positive lesions using the FLAIRTSE images; tseFPUF = corresponding subset of FPUF recorded with FLAIRTSE. 1 Cortex, in particular. 2 CNR and SNR are also partly involved.
Table 11. Conspicuity ratings of lesions in the FLAIRUF images, categorized by size and location.
Table 11. Conspicuity ratings of lesions in the FLAIRUF images, categorized by size and location.
Conspicuity
SizeLocation12345TP3Dap
nnnnnn
Large
(≥3 mm total)
All37180301314274<0.001 3
Small
(<3 mm)
All1294384480268
Large
(≥3 mm total)
Frontal755443730.002 4
Parietal54064358
Temporal124872372
Occipital6900015
Central 13783122
Infratentorial 242150434
Small
(<3 mm)
Frontal7461616251100.15 4
Parietal2201062260
Temporal3167142060
Occipital001113
Central 1011451131
Infratentorial 2010214
Large
(≥3 mm total)
Frontal755443730.42 4
Parietal54064358
Temporal124872372
Infratentorial 242150434
Small
(≥3 mm total)
Occipital6900015
0.002 3
Frontal and Parietal and
Temporal and Infratentorial 2
28164221013237
0.01 3
Central 13783122
Note. TP3Da = true-positive lesion counts using FLAIR3Da. The counts of lesions are given. The conspicuity was rated on an ordinal five-point Likert scale, based on the FLAIR3Da images: 1 = better/larger in the FLAIRUF images; 2 = equal; 3 = better in the FLAIR3Da images but classified as a lesion using only the FLAIRUF images; 4 = better in the FLAIR3Da images and classified as no lesion using only the FLAIRUF images; 5 = FLAIR3Da lesion that is not visible at all in the FLAIRUF images. 1 Insular lobe, corpus callosum, basal nuclei, and diencephalon. 2 Brainstem and cerebellum. 3 Wilcoxon rank-sum test. 4 Kruskal–Wallis test.
Table 12. Average lesion diameters (lengthwise), grouped by size category and location.
Table 12. Average lesion diameters (lengthwise), grouped by size category and location.
LocationLarge (≥3 mm total)Small (<3 mm)
TP3DaM and 95% CI
[LL, UL]
SDMdnpTP3DaM and 95% CI
[LL, UL]
SDMdnp
nmmmmmmnmmmmmm
Frontal735.1 [4.6, 5.6]1.94.60.261102.1 [2.0, 2.2]0.52.30.06
Parietal585.8 [5.0, 6.7]3.24.6602.1 [1.9, 2.2]0.62.1
Temporal725.3 [4.7, 5.9]2.54.6602.0 [1.8, 2.1]0.62.1
Occipital155.6 [4.6, 6.6]1.85.432.8 [2.6, 2.9]0.12.8
Central225.5 [3.8, 7.2]3.84.5312.2 [2.1, 2.4]0.52.4
Infratentorial346.5 [5.4, 7.5]3.05.242.3 [1.9, 2.8]0.32.4
Total2745.5 [5.2, 5.9]2.74.7 2682.1 [2.0, 2.2]0.62.2
Note. M = mean; CI = confidence interval; LL = lower limit; UL = upper limit; SD = standard deviation; Mdn = median; further abbreviations and brain regions as in Table 11. Since the assumptions of normal distribution of the data were not met, a Kruskal–Wallis test was performed.
Table 13. Conspicuity ratings of large lesions (≥3 mm), grouped by width category and location.
Table 13. Conspicuity ratings of large lesions (≥3 mm), grouped by width category and location.
LocationWide
(≥3 mm × ≥2 mm)
Narrow
(≥3 mm × <2 mm)
Large
(≥3 mm Total)
ConspicuityTotalConspicuityTotalTP3Da
1234512345
nnnnnnnnnnnnn
Frontal735001430204423073
Parietal228210333124332558
Temporal530410407183133272
Occipital480001221000315
Central0451010333211222
Infratentorial3173022514202934
Total2112214331631658161011111274
Note. The counts of lesions are given. Abbreviations and brain regions as in Table 11.
Table 14. SNR and CNR in FLAIRUF and FLAIR3Da images.
Table 14. SNR and CNR in FLAIRUF and FLAIR3Da images.
ParameterFLAIRUFFLAIR3Dap
Mdn (IQR)M ± SDL/HMdn (IQR)M ± SDL/H
SNR3 (3–3)3.00 ± 0.003/31 (1–1)1.18 ± 0.391/2<0.001
CNR3 (2–3)2.53 ± 0.512/31 (1–1)1.18 ± 0.391/2<0.001
Note. N = 17. SNR = signal-to-noise ratio; CNR = contrast-to-noise ratio; Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. Both parameters were rated on an ordinal five-point Likert scale: 1 = very good; 2 = good; 3 = acceptable; 4 = mediocre/diagnostic; 5 = poor/non-diagnostic. The p-values were calculated using the Wilcoxon signed-rank test.
Table 15. Artifacts in the FLAIRUF and FLAIR3Da images.
Table 15. Artifacts in the FLAIRUF and FLAIR3Da images.
ArtifactsFLAIRUFFLAIR3Dap
Mdn (IQR)M ± SDL/HMdn (IQR)M ± SDL/H
Distortions
 Frontal3 (2–3)2.6 ± 0.61/30 (0–0)0.0 ± 0.00/0<0.001
 Frontobasal3 (2–3)2.7 ± 0.52/30 (0–0)0.0 ± 0.00/0<0.001
 Temporopolar3 (2.5–3)2.8 ± 0.42/30 (0–0)0.0 ± 0.00/0<0.001
 Infratentorial1 (1–1)1.1 ± 0.31/20 (0–0)0.0 ± 0.00/0<0.001
Pulsatile flow
 infratentorial1 (1–4)2.2 ± 1.60/43 (3–4)3.4 ± 0.72/40.02
 supratentorial1 (0–1)0.7 ± 0.80/30 (0–0)0.0 ± 0.00/00.004
Chemical shift
 Frontal0 (0–0)0.1 ± 0.30/10 (0–0)0.0 ± 0.00/00.16
Residual Aliasing
 Central0 (0–0)0.2 ± 0.60/20 (0–0)0.0 ± 0.00/00.10
Spikes 10 (0–1)0.4 ± 0.60/20 (0–0)0.0 ± 0.00/00.03
Subject motion0 (0–0)0.0 ± 0.00/00 (0–0)0.1 ± 0.20/10.32
Note. N = 17. Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. All artifacts were rated on an ordinal five-point Likert scale: 0 = no artifact; 1 = artifact exists, but diagnostic information is not limited; 2 = artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = artifact exists, and diagnostic information is limited in the artifact region; 4 = artifact exists, and diagnostic information is severely limited in the artifact region. The p-values were calculated using the Wilcoxon signed-rank test. 1 In the case of a positive rating, artifacts only occurred in one single image slice each.
Table 16. SNR and CNR in FLAIRUF and FLAIRTSE images.
Table 16. SNR and CNR in FLAIRUF and FLAIRTSE images.
ParameterFLAIRUFFLAIRTSE
Mdn (IQR)M ± SDL/HMdn (IQR)M ± SDL/H
SNR3 (3–3)3.00 ± 0.003/33 (3–3)3.00 ± 0.003/3
CNR3 (2.5–3)2.67 ± 0.582/32 (2–2)2.00 ± 0.002/2
Note. N = 3. SNR = signal-to-noise ratio; CNR = contrast-to-noise ratio; Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. Both parameters were rated on an ordinal five-point Likert scale: 1 = very good; 2 = good; 3 = acceptable; 4 = mediocre/diagnostic; 5 = poor/non-diagnostic. Significance testing was omitted due to the low number of cases.
Table 17. Artifacts in the FLAIRUF and FLAIRTSE images.
Table 17. Artifacts in the FLAIRUF and FLAIRTSE images.
ArtifactsFLAIRUFFLAIRTSE
Mdn (IQR)M ± SDL/HMdn (IQR)M ± SDL/H
Distortions
 Frontal3 (3–3)3.0 ± 0.03/30 (0–0)0.0 ± 0.00/0
 Frontobasal3 (3–3)3.0 ± 0.03/30 (0–0)0.0 ± 0.00/0
 Temporopolar3 (3–3)3.0 ± 0.03/30 (0–0)0.0 ± 0.00/0
 Infratentorial1 (1–1)1.0 ± 0.01/10 (0–0)0.0 ± 0.00/0
Pulsatile flow
 infratentorial1 (1–1)1.0 ± 0.01/12 (1.5–3)2.3 ± 1.51/4
 supratentorial0 (0–0)0.0 ± 0.00/00 (0–0.5)0.3 ± 0.60/1
Chemical shift
 Frontal0 (0–0)0.0 ± 0.00/00 (0–0)0.0 ± 0.00/0
Residual Aliasing
 Central0 (0–1)0.7 ± 1.20/20 (0–0)0.0 ± 0.00/0
Spikes 10 (0–0.5)0.3 ± 0.60/10 (0–0)0.0 ± 0.00/0
Subject motion0 (0–0)0.0 ± 0.00/00 (0–0.5)0.3 ± 0.60/1
Note. N = 3. Mdn = median; IQR = interquartile range; M = mean; SD = standard deviation; L = lowest value; H = highest value. All artifacts were rated on an ordinal five-point Likert scale: 0 = no artifact; 1 = artifact exists, but diagnostic information is not limited; 2 = artifact exists, and diagnostic information is slightly limited in the artifact region; 3 = artifact exists, and diagnostic information is limited in the artifact region; 4 = artifact exists, and diagnostic information is severely limited in the artifact region. Significance testing was omitted due to the low number of cases. 1 In the case of a positive rating, artifacts only occurred in one single image slice each.
Table 18. FLAIRUF: SNR assessment in the vicinity of TPGS lesions, categorized by location.
Table 18. FLAIRUF: SNR assessment in the vicinity of TPGS lesions, categorized by location.
SNR Substandard Yes Percentage
LocationYesNoTPGS95% CI [LL, UL]p
nnn%
All14742156825.9 [22.3, 29.7]
Frontal2716319014.2 [9.6, 20.0]Diagnostics 14 01841 i001<0.001Diagnostics 14 01841 i0020.07
Parietal299112024.2 [16.8, 32.8]
Temporal2411113517.8 [11.7, 25.3]
Occipital117185.6 [0.1, 27.3]
Central35195464.8 [50.6, 77.3]Diagnostics 14 01841 i0030.67
Infratentorial31205160.8 [46.1, 74.2]
Frontal and Parietal and
Temporal and Occipital
8138246317.5 [14.1, 21.3]Diagnostics 14 01841 i004<0.001
Central and Infratentorial663910562.9 [52.9, 72.1]
Note. SNR = signal-to-noise ratio; TPGS = true-positive lesion counts using the gold standard; CI = confidence interval (Clopper–Pearson); LL = lower limit; UL = upper limit. Brain regions as in Table 11. The p-values were calculated using the chi-squared test.
Table 19. FLAIRUF: CNR assessment in the vicinity of TPGS lesions, categorized by location.
Table 19. FLAIRUF: CNR assessment in the vicinity of TPGS lesions, categorized by location.
CNR Substandard Yes Percentage
LocationYesNoTPGS95% CI [LL, UL]p
nnn%
All335355685.8 [4.0, 8.1]
Frontal61841903.2 [1.2, 6.8]Diagnostics 14 01841 i005<0.001Diagnostics 14 01841 i0060.15
Parietal71131205.8 [2.4, 11.6]
Temporal21331351.5 [0.2, 5.2]
Occipital018180.0 [0.0, 18.5]
Central054540.0 [0.0, 6.6]
Infratentorial18335135.3 [22.4, 49.9]
Frontal and Parietal and Temporal and Occipital and Central155025172.9 [1.6, 4.7]Diagnostics 14 01841 i007<0.001
Infratentorial18335135.3 [22.4, 49.9]
Note. CNR = contrast-to-noise ratio; further abbreviations as in Table 18. Brain regions as in Table 11. The p-values were calculated using the chi-squared test.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Schuhholz, M.; Ruff, C.; Bürkle, E.; Feiweier, T.; Clifford, B.; Kowarik, M.; Bender, B. Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence. Diagnostics 2024, 14, 1841. https://doi.org/10.3390/diagnostics14171841

AMA Style

Schuhholz M, Ruff C, Bürkle E, Feiweier T, Clifford B, Kowarik M, Bender B. Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence. Diagnostics. 2024; 14(17):1841. https://doi.org/10.3390/diagnostics14171841

Chicago/Turabian Style

Schuhholz, Martin, Christer Ruff, Eva Bürkle, Thorsten Feiweier, Bryan Clifford, Markus Kowarik, and Benjamin Bender. 2024. "Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence" Diagnostics 14, no. 17: 1841. https://doi.org/10.3390/diagnostics14171841

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop